JP2012232937A - Composition for oral cavity - Google Patents
Composition for oral cavity Download PDFInfo
- Publication number
- JP2012232937A JP2012232937A JP2011102948A JP2011102948A JP2012232937A JP 2012232937 A JP2012232937 A JP 2012232937A JP 2011102948 A JP2011102948 A JP 2011102948A JP 2011102948 A JP2011102948 A JP 2011102948A JP 2012232937 A JP2012232937 A JP 2012232937A
- Authority
- JP
- Japan
- Prior art keywords
- mass
- composition
- acid
- sodium
- dentin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 143
- 210000000214 mouth Anatomy 0.000 title claims abstract description 27
- 150000002222 fluorine compounds Chemical class 0.000 claims abstract description 41
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 35
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 34
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 34
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 34
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 32
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000002253 acid Substances 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910017604 nitric acid Inorganic materials 0.000 claims abstract description 16
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 15
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 15
- 210000004268 dentin Anatomy 0.000 claims description 65
- 102000007544 Whey Proteins Human genes 0.000 claims description 41
- 108010046377 Whey Proteins Proteins 0.000 claims description 41
- 239000005862 Whey Substances 0.000 claims description 39
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 30
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 30
- 235000002639 sodium chloride Nutrition 0.000 claims description 26
- 206010020751 Hypersensitivity Diseases 0.000 claims description 23
- 208000026935 allergic disease Diseases 0.000 claims description 23
- 230000009610 hypersensitivity Effects 0.000 claims description 23
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 16
- 239000004323 potassium nitrate Substances 0.000 claims description 15
- 235000010333 potassium nitrate Nutrition 0.000 claims description 15
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- 239000002324 mouth wash Substances 0.000 claims description 12
- 229940051866 mouthwash Drugs 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000000551 dentifrice Substances 0.000 claims description 10
- 239000004317 sodium nitrate Substances 0.000 claims description 8
- 235000010344 sodium nitrate Nutrition 0.000 claims description 8
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 22
- 208000002925 dental caries Diseases 0.000 abstract description 13
- 235000013336 milk Nutrition 0.000 abstract description 13
- 239000008267 milk Substances 0.000 abstract description 13
- 210000004080 milk Anatomy 0.000 abstract description 13
- 208000035154 Hyperesthesia Diseases 0.000 abstract 1
- 159000000001 potassium salts Chemical class 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 229940034610 toothpaste Drugs 0.000 description 40
- 239000000606 toothpaste Substances 0.000 description 40
- 230000000052 comparative effect Effects 0.000 description 35
- 238000011156 evaluation Methods 0.000 description 34
- -1 fatty acid salt Chemical class 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 29
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 23
- 210000005239 tubule Anatomy 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 15
- 229910052731 fluorine Inorganic materials 0.000 description 15
- 239000011737 fluorine Substances 0.000 description 15
- 208000008655 root caries Diseases 0.000 description 15
- 239000011775 sodium fluoride Substances 0.000 description 15
- 235000013024 sodium fluoride Nutrition 0.000 description 15
- 229960000414 sodium fluoride Drugs 0.000 description 15
- 239000003205 fragrance Substances 0.000 description 14
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 13
- 230000001629 suppression Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 12
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 12
- 229960002216 methylparaben Drugs 0.000 description 12
- 201000009241 dentin caries Diseases 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000008213 purified water Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 10
- 239000000120 Artificial Saliva Substances 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 210000003298 dental enamel Anatomy 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 229940085605 saccharin sodium Drugs 0.000 description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 9
- 238000005115 demineralization Methods 0.000 description 9
- 230000002328 demineralizing effect Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 229940091249 fluoride supplement Drugs 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 9
- 239000000600 sorbitol Substances 0.000 description 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 235000010413 sodium alginate Nutrition 0.000 description 8
- 239000000661 sodium alginate Substances 0.000 description 8
- 229940005550 sodium alginate Drugs 0.000 description 8
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 8
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000012085 test solution Substances 0.000 description 6
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000013329 compounding Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000272185 Falco Species 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001680 brushing effect Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- 239000004711 α-olefin Substances 0.000 description 4
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 3
- 102000013563 Acid Phosphatase Human genes 0.000 description 3
- 108010051457 Acid Phosphatase Proteins 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000003082 abrasive agent Substances 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010001682 Dextranase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 108010023244 Lactoperoxidase Proteins 0.000 description 2
- 102000045576 Lactoperoxidases Human genes 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000025371 Taste disease Diseases 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940057428 lactoperoxidase Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000019656 metallic taste Nutrition 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108010060806 Photosystem II Protein Complex Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000002599 Smear Layer Diseases 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000002170 dentin sensitivity Diseases 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 201000010840 enamel caries Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- DWYMPOCYEZONEA-UHFFFAOYSA-L fluoridophosphate Chemical compound [O-]P([O-])(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-L 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000008233 hard water Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940074371 monofluorophosphate Drugs 0.000 description 1
- 229940005638 monofluorophosphate ion Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000010585 negative regulation of hypersensitivity Effects 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 229940093928 potassium nitrate Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 235000019600 saltiness Nutrition 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 1
- 229940001516 sodium nitrate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- YUOWTJMRMWQJDA-UHFFFAOYSA-J tin(iv) fluoride Chemical compound [F-].[F-].[F-].[F-].[Sn+4] YUOWTJMRMWQJDA-UHFFFAOYSA-J 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は口腔用組成物に関する。 The present invention relates to an oral composition.
知覚過敏症(象牙質知覚過敏症)とは、歯のエナメル質又はセメント質が消失して象牙質が露出し、露出した象牙質に温度的、化学的、又は機械的な外来刺激が与えられることによって生じる、一過性の、非常に不快な痛みである。痛みの原因は、象牙細管を通じて神経に外来刺激が伝わるためと考えられている。 Hypersensitivity (dentin hypersensitivity) is the loss of dental enamel or cement, exposing dentin, and exposing exposed dentin to thermal, chemical, or mechanical external stimuli. It is a temporary, very unpleasant pain. The cause of pain is thought to be that external stimuli are transmitted to nerves through dentinal tubules.
歯磨剤などの口腔衛生製品による知覚過敏の抑制に関する技術としては、象牙細管を封鎖する方法、神経を鈍麻する方法が知られている。 As a technique relating to suppression of hypersensitivity by oral hygiene products such as dentifrices, a method of blocking dentinal tubules and a method of blunting nerves are known.
象牙細管を封鎖する方法としては例えば、乳酸アルミニウムを用いる方法が知られている。乳酸アルミニウムは、象牙細管の開口部を塞ぐ作用を有するとともに、歯肉の収斂作用を有する(特許文献1および2;特開平7−291844号公報および特開2003−26556号公報)。 As a method for sealing the dentinal tubule, for example, a method using aluminum lactate is known. Aluminum lactate has the effect of closing the opening of the dentinal tubule and has the effect of converging gingiva (Patent Documents 1 and 2; JP-A-7-291844 and JP-A-2003-26556).
神経を鈍麻する方法としては、硝酸カリウム等のカリウム塩を用いる方法が知られている(特許文献3;特開2003−73246号公報、特許文献4:特表2004−506663号公報)。 As a method for dulling nerves, a method using a potassium salt such as potassium nitrate is known (Patent Document 3; JP-A-2003-73246, Patent Document 4: JP-T-2004-506663).
象牙質う蝕は、エナメル質う蝕によりエナメル質が崩壊した後に象牙質が露出することで発症する。また、歯周病や加齢等により歯肉の退縮が起こり、歯根部が露出することでも発症する。象牙質は、細管構造を持つことおよび歯質にコラーゲンを有することから、エナメル質と比較して物理的および化学的に脆弱であるとされ、エナメル質よりもフッ素等の薬剤が効きにくいと言われている。よって、通常のう蝕(エナメル質がある状態のう蝕)と比較して、象牙質う蝕の予防は困難なことが多い。また、通常のう蝕の予防法が象牙質う蝕の予防には十分な効果を奏しない場合もある。 Dentin caries develops when dentin is exposed after enamel collapses due to enamel caries. In addition, gingival recession occurs due to periodontal disease, aging, and the like, and the tooth root portion is exposed, and the onset occurs. Dentin is considered to be physically and chemically weaker than enamel because it has a tubule structure and collagen in the tooth, and says that drugs such as fluorine are less effective than enamel. It has been broken. Therefore, it is often difficult to prevent dentin caries compared to normal caries (caries with enamel). In addition, the usual caries prevention methods may not be effective enough to prevent dentin caries.
露出した歯根部に発症する象牙質う蝕は、根面う蝕と呼ばれる。根面う蝕は、歯と歯ぐきの隙間に溜まる歯垢中の酸または酵素によって発症する。根面う蝕は、気づかないうちに急速に進行する。痛みを感じることが少なく、見つけにくい場所に発症しやすることが多い。よって、気づいた時には既に重度に進行していることが多く、治療が困難であり抜歯の可能性が高いとされる。これらの点から、根面う蝕は、歯冠部等に発症する通常の象牙質う蝕とは区別して扱われることが多い。特に最近、根面う蝕に対しては通常のう蝕とは異なる、つまり根面う蝕の確実な予防手段が必要とされている。 Dentin caries that develops in the exposed root is called root caries. Root caries is caused by acids or enzymes in plaque that accumulate in the gap between the teeth and gums. Root caries progress rapidly without being noticed. It often occurs in places that are less painful and difficult to find. Therefore, when it is noticed, it has already progressed severely, and it is difficult to treat and the possibility of tooth extraction is high. From these points, root caries are often treated separately from normal dentin caries that develops in the crown and the like. In particular, recently, there is a need for root caries that is different from normal caries, that is, reliable preventive measures for root caries.
通常の象牙質う蝕の予防手段として、歯質保護を謳う技術及び歯質そのものを強化する技術が提案されている。 As a usual means for preventing dentin caries, a technique for encouraging tooth protection and a technique for strengthening the tooth itself have been proposed.
歯質保護を謳う技術としては例えば、天然または合成のカチオン化ペプチドまたはタンパクと、ノニオン性界面活性剤および両性界面活性剤から選ばれる少なくとも1種の界面活性剤と、さらにフッ化物を含む、アニオン性界面活性剤不含口腔用組成物による、歯牙表面へのフッ素取り込み量の向上に関する技術(特許文献5:特開平6−9354号公報)、コラーゲンまたはゼラチンを含有する口腔用剤による、生体組織の保護に関する技術(特許文献6:特開2003−119157号公報)、脂肪酸塩が配合されている歯面コート剤による歯垢形成の予防に関する技術(特許文献7:特開2000−103726号公報)が挙げられる。 Examples of the technology for protecting tooth properties include natural or synthetic cationized peptides or proteins, at least one surfactant selected from nonionic surfactants and amphoteric surfactants, and an anion containing fluoride. For improving the amount of fluorine taken into the tooth surface by the oral surfactant-free composition (Patent Document 5: Japanese Patent Laid-Open No. 6-9354), living tissue by the oral preparation containing collagen or gelatin (Patent Document 6: Japanese Patent Laid-Open No. 2003-119157), technology related to prevention of plaque formation by a tooth surface coating agent containing a fatty acid salt (Patent Document 7: Japanese Patent Laid-Open No. 2000-103726) Is mentioned.
歯質そのものを強化する技術としては、例えば、フッ素化合物を含む石化海藻と酸とキシリトールを有効成分とする歯質強化剤により歯牙エナメル質および象牙質の耐酸性を向上させる技術(特許文献8:特開2008−127304号公報)、ラクトフェリン、ラクトパーオキシダーゼ、茶ポリフェノール、またはフッ素からなる群から選択される2以上の成分を含有する低う蝕性栄養組成物による虫歯予防に関する技術(特許文献9:特開平9−107917号公報)が挙げられる。 As a technique for strengthening the tooth itself, for example, a technique for improving acid resistance of tooth enamel and dentin by using a fossilized seaweed containing a fluorine compound and a tooth strengthening agent containing acid and xylitol as active ingredients (Patent Document 8: JP, 2008-127304, A), technology related to dental caries prevention by low caries nutrition composition containing two or more components selected from the group consisting of lactoferrin, lactoperoxidase, tea polyphenol, or fluorine (Patent Document 9) : JP-A-9-107917).
しかし、知覚過敏の抑制に関する上記公知技術はいずれも、以下のような課題を抱えている。 However, all of the above-described known techniques relating to suppression of hypersensitivity have the following problems.
乳酸アルミニウムを含む口腔用組成物により十分に象牙細管を封鎖させるためには、配合量を数%オーダーとすることが必要である。その結果、乳酸アルミニウム特有のえぐみや金属味の発現、組成物の安定性の悪化等の問題が生じるおそれがある。また、硝酸カリウムの神経鈍磨作用は、即効性があるものの、苦味が強く使用に不快感を伴うほか、効果の持続性が低い等の問題がある。 In order to sufficiently seal the dentinal tubules with the oral composition containing aluminum lactate, it is necessary to make the blending amount on the order of several percent. As a result, there is a possibility that problems such as the peculiarity of aluminum lactate, the appearance of a metallic taste, and the deterioration of the stability of the composition may occur. Moreover, although the nerve dulling action of potassium nitrate has an immediate effect, there are problems such as strong bitterness and uncomfortable use, and low sustained effect.
このような従来の技術の問題点を解消し、知覚過敏の抑制効果を飛躍的に向上させることのできる、新しい技術が待望されていた。 There has been a long-awaited need for a new technology that can solve the problems of the conventional technology and can dramatically improve the effect of suppressing hypersensitivity.
一方、歯質保護および歯質そのものの強化に関する上記公知技術はいずれも、以下のような問題を抱えている。 On the other hand, all of the above-mentioned known techniques relating to the protection of the tooth and the strengthening of the tooth itself have the following problems.
歯質保護技術の問題点は、以下の通りである。特許文献5の口腔用組成物は、フッ素の歯面取り込みに長時間を要する。特許文献6の技術は、象牙質に含まれるI型コラーゲンに対しては吸着能が小さいため、象牙質の保護を十分に行えない可能性がある。特許文献7の技術は、脂肪酸塩は界面活性作用を有するため、歯面コート剤の処置後うがいをすると、脂肪酸塩が口腔内から流出し、歯面滞留性が不十分となり易い。 The problems of the dental protection technology are as follows. The composition for oral cavity of patent document 5 requires a long time for tooth surface uptake | capture of a fluorine. The technique of Patent Document 6 has a low adsorbability for type I collagen contained in dentin, and thus may not be able to sufficiently protect dentin. In the technique of Patent Document 7, since the fatty acid salt has a surface-active action, when the tooth surface coating agent is gargled after treatment, the fatty acid salt tends to flow out of the oral cavity and the tooth surface retention tends to be insufficient.
歯質の強化に関する技術の問題点は、以下の通りである。特許文献8の歯質強化剤は、根面う蝕への実効性に疑問が残る。特許文献9の技術では、口腔用組成物ではなく食品組成物であり、しかも乳児用であることから、象牙質う蝕、中でも根面う蝕に対する有効性に対しては疑念を払拭できない。 The technical problems related to the enhancement of tooth quality are as follows. The tooth enhancer of Patent Document 8 has doubts about its effectiveness for root caries. In the technique of Patent Document 9, since it is not a composition for oral cavity but a food composition, and it is for infants, the suspicion cannot be dispelled for its effectiveness against dentin caries, especially root caries.
このような従来の技術の問題点を解消し、エナメル質よりも有効成分が効きにくい象牙質う蝕の予防効果、特に根面う蝕の予防効果を飛躍的に向上させる新しい技術が待望されていた。 There is a long-awaited new technology that eliminates the problems of the conventional technology and dramatically improves the preventive effect of dentine caries, especially the root caries. It was.
本発明は、上記に鑑みてなされたものであって、知覚過敏を顕著に抑制することができ、かつ、根面う蝕を含む象牙質う蝕を顕著に予防することができる技術を提供することを目的とする。 The present invention has been made in view of the above, and provides a technique capable of remarkably suppressing hypersensitivity and remarkably preventing dentin caries including root caries. For the purpose.
本発明者らは鋭意検討を重ねた。その結果、乳清またはラクトフェリン、フッ素化合物および特定の酸塩を含む組成物が、可溶性フッ素化合物を安定して保有すること、および、象牙細管を封鎖し知覚過敏を顕著に抑制することができることを見出した。また、該組成物は、石灰化を促進し象牙質の耐酸性および硬さを飛躍的に向上させることを確認すると共に、使用感にも優れていることを見出した。本発明は係る知見に基づくものである。 The present inventors made extensive studies. As a result, the composition containing whey or lactoferrin, a fluorine compound, and a specific acid salt stably retains a soluble fluorine compound, and can block dentinal tubules and significantly suppress hypersensitivity. I found it. Moreover, while confirming that this composition accelerates | stimulates calcification and improves the acid resistance and hardness of dentine drastically, it discovered that it was excellent also in the usability | use_condition. The present invention is based on such knowledge.
本発明は、以下の〔1〕〜〔8〕を提供する。
〔1〕(A):乳清および/またはラクトフェリン、(B):フッ素化合物、および、(C):硝酸、塩酸、リン酸および硫酸から選ばれる酸の、カリウム塩およびナトリウム塩よりなる群から選ばれる少なくとも1種の塩を含有する、口腔用組成物。
〔2〕前記(A)の前記(C):に対する質量比((A)/(C))が、0.01〜3である、上記〔1〕に記載の口腔用組成物。
〔3〕前記(C)が、硝酸カリウム、硝酸ナトリウム、塩化ナトリウム及び塩化カリウムから選ばれる少なくとも1種である、上記〔1〕又は〔2〕に記載の口腔用組成物。
〔4〕歯磨組成物または洗口組成物である、上記〔1〕〜〔3〕のいずれか一項に記載の口腔用組成物。
〔5〕(A):乳清および/またはラクトフェリン、(B):フッ素化合物、および、(C):硝酸、塩酸、リン酸および硫酸のカリウム塩およびナトリウム塩よりなる群から選ばれる少なくとも1種を含有する知覚過敏抑制組成物。
〔6〕(A):乳清および/またはラクトフェリン、および、(C):硝酸、塩酸、リン酸および硫酸のカリウム塩およびナトリウム塩よりなる群から選ばれる少なくとも1種を含有する、フッ素化合物を含む口腔用組成物用の、可溶性フッ素化合物安定性向上組成物。
〔7〕(A):乳清および/またはラクトフェリン、(B):フッ素化合物、および、(C):硝酸、塩酸、リン酸および硫酸のカリウム塩およびナトリウム塩よりなる群から選ばれる少なくとも1種を含有する象牙質の硬さ向上組成物。
〔8〕(A):乳清および/またはラクトフェリン、(B):フッ素化合物、および、(C):硝酸、塩酸、リン酸および硫酸のカリウム塩およびナトリウム塩よりなる群から選ばれる少なくとも1種を含有する象牙質の耐酸性向上組成物。
The present invention provides the following [1] to [8].
[1] (A): Whey and / or lactoferrin, (B): Fluorine compound, and (C): From the group consisting of potassium salt and sodium salt of an acid selected from nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid An oral composition containing at least one selected salt.
[2] The composition for oral cavity according to the above [1], wherein the mass ratio of (A) to (C): ((A) / (C)) is 0.01 to 3.
[3] The composition for oral cavity according to [1] or [2] above, wherein (C) is at least one selected from potassium nitrate, sodium nitrate, sodium chloride and potassium chloride.
[4] The composition for oral cavity according to any one of the above [1] to [3], which is a dentifrice composition or a mouthwash composition.
[5] (A): whey and / or lactoferrin, (B): fluorine compound, and (C): at least one selected from the group consisting of potassium and sodium salts of nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid A composition for suppressing hypersensitivity, comprising:
[6] A fluorine compound containing (A): whey and / or lactoferrin, and (C): at least one selected from the group consisting of potassium salt and sodium salt of nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid. A composition for improving the stability of a soluble fluorine compound for an oral composition containing the composition.
[7] (A): whey and / or lactoferrin, (B): fluorine compound, and (C): at least one selected from the group consisting of potassium salt and sodium salt of nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid Containing dentin hardness improving composition.
[8] (A): whey and / or lactoferrin, (B): fluorine compound, and (C): at least one selected from the group consisting of potassium and sodium salts of nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid A composition for improving acid resistance of dentin.
本発明の口腔用組成物は、可溶性フッ素化合物を安定して保有することができ、象牙細管を封鎖することができ、かつ、石灰化を促進し象牙質の耐酸性および硬さを飛躍的に向上させることができる。よって、本発明の組成物は、知覚過敏を抑制すると共に、根面う蝕を含む象牙質う蝕を顕著に予防することができる。本発明の組成物は、使用感にも優れているので、例えば歯磨組成物、洗口組成物等各種の口腔用組成物として有用である。 The composition for oral cavity of the present invention can stably hold a soluble fluorine compound, can seal dentinal tubules, promotes calcification, and dramatically improves the acid resistance and hardness of dentin. Can be improved. Therefore, the composition of the present invention can remarkably prevent dentin caries including root caries while suppressing hypersensitivity. Since the composition of the present invention is excellent in usability, it is useful as various oral compositions such as a dentifrice composition and a mouthwash composition.
本発明の口腔用組成物は、(A):乳清および/またはラクトフェリン、(B):フッ素化合物、および(C):硝酸、塩酸、リン酸および硫酸から選ばれる酸の、カリウム塩およびナトリウム塩よりなる群から選ばれる少なくとも1種の塩を含有する。 The composition for oral cavity of the present invention comprises (A): whey and / or lactoferrin, (B): fluorine compound, and (C): potassium salt and sodium of an acid selected from nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid. It contains at least one salt selected from the group consisting of salts.
(A)は、乳清のみでもよいし、ラクトフェリンのみでもよいし、乳清とラクトフェリンの組み合わせであってもよい。 (A) may be whey only, lactoferrin only, or a combination of whey and lactoferrin.
乳清およびラクトフェリンは、一般に乳由来物として知られている。牛乳には、通常、約3.3質量%のタンパク質が含まれ、そのうち約80質量%がカゼインであり、残りの約20質量%が乳清である。乳清は、チーズやヨーグルトを製造する際に分離される上澄み部分である。乳清は、殆どが水分であるが、約1質量%のタンパク質(乳清タンパク質)を含有する。乳清タンパク質は、その約40質量%がβ−ラクトグロブリン、約20質量%がα−ラクトアルブミン、約6質量%がラクトフェリンであり、その他血清アルブミン、免疫グロブリンなどを含む。 Whey and lactoferrin are generally known as milk products. Milk typically contains about 3.3% protein by weight, of which about 80% is casein and the remaining about 20% is whey. Whey is the supernatant portion that is separated when producing cheese or yogurt. Whey is mostly water but contains about 1% by weight protein (whey protein). About 40% by mass of whey protein is β-lactoglobulin, about 20% by mass is α-lactalbumin, about 6% by mass is lactoferrin, and also contains serum albumin, immunoglobulin and the like.
乳清の製造方法に特に制限は無いが、通常は、上記のごとくチーズやヨーグルトを製造する際の上清を分離し、脱塩、脱臭、脱色などの精製過程を経て製造される。乳清として市販品を用いてもよい。市販品としては、例えば、液体原料(例えば、FMエキス、FMエキスLA(いずれも一丸ファルコス(株)製))、および、液体を濃縮し粉末化した原料(ホエイパウダー、ホエイパウダーDX(いずれも森永乳業(株)製))が挙げられる。 Although there is no restriction | limiting in particular in the manufacturing method of whey, Usually, as mentioned above, the supernatant at the time of manufacturing cheese and yogurt is isolate | separated, and it manufactures through purification processes, such as desalting, deodorizing, and decoloring. A commercial product may be used as the whey. Examples of commercially available products include liquid raw materials (for example, FM extract and FM extract LA (both manufactured by Ichimaru Falcos Co., Ltd.)), and raw materials obtained by concentrating liquid into powder (whey powder, whey powder DX (both Morinaga Milk Industry Co., Ltd.)).
ラクトフェリンの製造方法に特に制限は無いが、通常は、脱脂乳または乳清からラクトフェリンを含む画分を分離し、さらに精製することで製造される。例えば、イオン交換樹脂と脱脂乳または乳清とを接触させた後、イオン交換樹脂に吸着していない成分を水洗で除去し、低濃度の塩溶液でラクトパーオキシダーゼを溶出し、続いて高濃度の塩溶液でラクトフェリンを溶出し回収する方法が挙げられる。また、回収後のラクトフェリンを、必要に応じて、濃縮、乾燥、粉末化等を行ってもよい。ラクトフェリンとしては、市販品を用いてもよい。市販品としては、例えば、粉末化原料(例えば、MLF−1、MLF−EX(いずれも森永乳業(株)製))、液体原料(例えば、ラクトフェリンS、ラクトフェリンSL(いずれも一丸ファルコス(株)製))等が挙げられる。 Although there is no restriction | limiting in particular in the manufacturing method of lactoferrin, Usually, it manufactures by isolate | separating and further refine | purifying the fraction containing lactoferrin from skim milk or whey. For example, after contacting the ion exchange resin with skim milk or whey, the components not adsorbed on the ion exchange resin are removed by washing with water, and lactoperoxidase is eluted with a low concentration salt solution, followed by high concentration. The method of eluting and recovering lactoferrin with a salt solution of Further, the collected lactoferrin may be concentrated, dried, powdered or the like as necessary. A commercially available product may be used as lactoferrin. Examples of commercially available products include powdered raw materials (for example, MLF-1, MLF-EX (both manufactured by Morinaga Milk Industry Co., Ltd.)), liquid raw materials (for example, lactoferrin S, lactoferrin SL (both are Ichimaru Falcos) Manufactured)) and the like.
本発明の口腔用組成物における(A)の配合量の下限は、組成物全体の固形分(乾燥(例えば105℃、6時間)後の蒸発残分)として、好ましくは0.005質量%以上、より好ましくは0.01質量%以上である。0.005質量%以上であることにより、知覚過敏の抑制、象牙質の耐酸性の向上、象牙質の硬さの向上および使用感の向上において、顕著な効果が得られる。配合量の上限は、好ましくは10質量%以下、より好ましくは3質量%以下である。10質量%以下であることにより、添加量に見合った量で、可溶性フッ素化合物の安定性を保持し、知覚過敏の抑制、象牙質の耐酸性の向上および象牙質の硬さの向上において顕著な効果が得られ、使用感もより良好に保持することができる。(A)の配合量は、好ましくは0.005〜10質量%、より好ましくは0.01〜3質量%である。 The lower limit of the blending amount of (A) in the oral composition of the present invention is preferably 0.005% by mass or more as the solid content of the entire composition (evaporation residue after drying (eg, 105 ° C., 6 hours)). More preferably, the content is 0.01% by mass or more. By being 0.005 mass% or more, a remarkable effect is acquired in suppression of hypersensitivity, improvement in acid resistance of dentin, improvement in dentin hardness, and improvement in feeling of use. The upper limit of the amount is preferably 10% by mass or less, more preferably 3% by mass or less. By being 10% by mass or less, the stability of the soluble fluorine compound is maintained in an amount commensurate with the addition amount, and it is remarkable in suppressing hypersensitivity, improving the acid resistance of dentin, and improving the hardness of dentin An effect is acquired and a usability | use_condition can be hold | maintained more favorably. The blending amount of (A) is preferably 0.005 to 10% by mass, more preferably 0.01 to 3% by mass.
(B)において、フッ素化合物とはフッ化物又はフッ化物塩を意味する。例えば、フッ化ナトリウム、モノフルオロリン酸ナトリウム、フッ化スズ等が挙げられる。好ましくは、フッ化ナトリウム、モノフルオロリン酸ナトリウムである。(B)フッ素化合物は、1種のフッ素化合物であってもよいし2種以上のフッ素化合物の組み合わせであってもよい。(B)フッ素化合物は、本発明の組成物中において、可溶性フッ素化合物として、すなわち、他の成分と結合しない状態で、有効性(主にう蝕予防)を発揮する。 In (B), the fluorine compound means fluoride or fluoride salt. Examples thereof include sodium fluoride, sodium monofluorophosphate, tin fluoride and the like. Sodium fluoride and sodium monofluorophosphate are preferred. (B) The fluorine compound may be a single fluorine compound or a combination of two or more fluorine compounds. (B) The fluorine compound exhibits effectiveness (mainly caries prevention) as a soluble fluorine compound in the composition of the present invention, that is, in a state where it is not bonded to other components.
本発明の口腔用組成物における、(B)フッ素化合物の配合量の下限は、好ましくは、フッ素原子として組成物全体の100ppm以上、より好ましくは500ppm以上である。100ppm以上であることにより象牙細管の封鎖および象牙質耐酸性の顕著な向上がもたらされ、知覚過敏を顕著に抑制することができる。配合量の上限は、好ましくは2000ppm以下、より好ましくは1500ppm以下である。2000ppm以下であることにより、可溶性フッ素化合物の安定性および良好な使用感を保持することができる。(B)成分の配合量は、好ましくは100〜2000ppm、より好ましくは500〜1500ppmである。 The lower limit of the blending amount of the (B) fluorine compound in the oral composition of the present invention is preferably 100 ppm or more, more preferably 500 ppm or more of the whole composition as fluorine atoms. By being 100 ppm or more, the dentinal tubule is blocked and the acid resistance of the dentin is remarkably improved, and hypersensitivity can be remarkably suppressed. The upper limit of the amount is preferably 2000 ppm or less, more preferably 1500 ppm or less. By being 2000 ppm or less, the stability of a soluble fluorine compound and a favorable feeling of use can be maintained. (B) The compounding quantity of a component becomes like this. Preferably it is 100-2000 ppm, More preferably, it is 500-1500 ppm.
(C)硝酸、塩酸、リン酸および硫酸から選ばれる酸の、カリウム塩およびナトリウム塩よりなる群から選ばれる少なくとも1種の塩とは、硝酸のカリウム塩、硝酸のナトリウム塩、塩酸のカリウム塩、塩酸のナトリウム塩、リン酸のカリウム塩、リン酸のナトリウム塩、硫酸のカリウム塩および硫酸のナトリウム塩よりなる群から選ばれる1種、または2種以上の組み合わせである。 (C) at least one salt selected from the group consisting of a potassium salt and a sodium salt of an acid selected from nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid is a potassium salt of nitric acid, a sodium salt of nitric acid, and a potassium salt of hydrochloric acid A sodium salt of hydrochloric acid, a potassium salt of phosphoric acid, a sodium salt of phosphoric acid, a potassium salt of sulfuric acid, and a sodium salt of sulfuric acid, or a combination of two or more.
(C)としては、例えば、硝酸カリウム、塩化カリウム、リン酸二水素カリウム、硫酸カリウム、炭酸カリウム、炭酸水素カリウム、硝酸ナトリウム、塩化ナトリウム、炭酸ナトリウム、炭酸水素ナトリウム、リン酸三ナトリウム、リン酸水素二ナトリウム、リン酸二水素ナトリウム、硫酸ナトリウムなどが挙げられる。これらのうち、有効性および使用性の観点から、硝酸カリウム、硝酸ナトリウム、塩化ナトリウム、塩化カリウムが好ましい。 Examples of (C) include potassium nitrate, potassium chloride, potassium dihydrogen phosphate, potassium sulfate, potassium carbonate, potassium hydrogen carbonate, sodium nitrate, sodium chloride, sodium carbonate, sodium hydrogen carbonate, trisodium phosphate, hydrogen phosphate. Examples include disodium, sodium dihydrogen phosphate, and sodium sulfate. Of these, potassium nitrate, sodium nitrate, sodium chloride, and potassium chloride are preferable from the viewpoints of effectiveness and usability.
本発明の口腔用組成物における、(C)塩の配合量の下限は、好ましくは0.1質量%以上、より好ましくは0.5質量%以上である。0.1質量%以上であることにより、可溶性フッ素化合物の安定性、知覚過敏の抑制、象牙質の耐酸性の向上および象牙質の硬さの向上において、顕著な効果を得ることができる。配合量の上限は、好ましくは10質量%以下、より好ましくは7質量%以下である。10質量%以下であることにより、金属味および塩味が抑えられ、使用感をより良好に保つことができる。(C)成分の配合量は、好ましくは0.1〜10質量%、より好ましくは0.5〜7質量%である。なお、本発明において、可溶性フッ素化合物とは、口腔用組成物において、液体(例えば、水等)に溶け、イオン状態になる(フッ化ナトリウムの場合、Na+とF-に、モノフルオロリン酸ナトリウムの場合、モノフルオロリン酸イオン(FPO3 2-)とNa+に解離する)性質を持つフッ素化合物を意味する。可溶性フッ素化合物は、他の成分と結合せず、フッ素としてう蝕予防効果を発揮できる状態にあるフッ素化合物と言い換えることもできる。 The lower limit of the amount of the (C) salt in the oral composition of the present invention is preferably 0.1% by mass or more, more preferably 0.5% by mass or more. When the content is 0.1% by mass or more, remarkable effects can be obtained in the stability of the soluble fluorine compound, the suppression of hypersensitivity, the improvement of acid resistance of the dentin, and the improvement of the hardness of the dentin. The upper limit of the amount is preferably 10% by mass or less, more preferably 7% by mass or less. By being 10 mass% or less, a metal taste and salty taste are suppressed and a usability | use_condition can be kept more favorable. (C) The compounding quantity of a component becomes like this. Preferably it is 0.1-10 mass%, More preferably, it is 0.5-7 mass%. In the present invention, the soluble fluorine compounds in oral compositions, liquid (e.g., water) soluble in the case of become ionic state (sodium fluoride, Na + and F -, the monofluorophosphate In the case of sodium, it means a fluorine compound having the property of monofluorophosphate ion (dissociated into FPO 3 2− ) and Na + ). The soluble fluorine compound can be paraphrased as a fluorine compound which is not bonded to other components and is in a state where it can exhibit a caries prevention effect as fluorine.
(A)の(C)に対する質量比((A)/(C))は、好ましくは0.001以上、より好ましくは0.01以上である。質量比が0.001以上であることにより、知覚過敏の抑制、象牙質の耐酸性の向上、および象牙質の硬さの向上において、顕著な効果を得ることができる。上限は、好ましくは5以下、より好ましくは3以下である。質量比が5以下であることにより、可溶性フッ素化合物の安定性において顕著な効果を得ることができる。質量比((A)/(C))は、好ましくは0.001〜5、より好ましくは0.01〜3である。 The mass ratio ((A) / (C)) of (A) to (C) is preferably 0.001 or more, more preferably 0.01 or more. When the mass ratio is 0.001 or more, remarkable effects can be obtained in suppression of hypersensitivity, improvement of acid resistance of dentin, and improvement of dentin hardness. The upper limit is preferably 5 or less, more preferably 3 or less. When the mass ratio is 5 or less, a remarkable effect can be obtained in the stability of the soluble fluorine compound. The mass ratio ((A) / (C)) is preferably 0.001 to 5, more preferably 0.01 to 3.
本発明の口腔用組成物には、本発明の目的に反しない範囲で、上記(A)〜(C)に加えて任意成分を配合することができる。任意成分としては、例えば、界面活性剤、粘結剤、粘稠剤、甘味剤、防腐剤、研磨剤、香料、薬用成分、溶媒が挙げられる。任意成分は、1種を用いてもよいし、2種以上の組み合わせを用いてもよい。該任意成分の配合量は、本発明の効果を損なわない範囲で調整することができる。 In the composition for oral cavity of the present invention, an optional component can be blended in addition to the above (A) to (C) within the range not contrary to the object of the present invention. Examples of optional components include surfactants, binders, thickeners, sweeteners, preservatives, abrasives, fragrances, medicinal ingredients, and solvents. As the optional component, one type may be used, or a combination of two or more types may be used. The compounding quantity of this arbitrary component can be adjusted in the range which does not impair the effect of this invention.
以下に任意成分の具体例を示すが、任意成分はこれらに制限されるものではない。 Although the specific example of an arbitrary component is shown below, an arbitrary component is not restrict | limited to these.
界面活性剤としては、例えば、アニオン性界面活性剤、ノニオン性界面活性剤等が挙げられる。界面活性剤は、1種を用いてもよいし、2種以上の組み合わせを用いてもよい。 Examples of the surfactant include an anionic surfactant and a nonionic surfactant. One type of surfactant may be used, or a combination of two or more types may be used.
アニオン性界面活性剤としては、例えば、N−アシルアミノ酸塩、α−オレフィンスルホン酸塩、N−アシルスルホン酸塩、アルキル硫酸塩、グリセリン脂肪酸エステルの硫酸塩、ラウロイルサルコシンナトリウム、アルキル鎖の炭素鎖長として炭素数が10〜16のα−オレフィンスルホン酸ナトリウム、ラウリル硫酸ナトリウムが挙げられる。汎用性の点で、N−アシルアミノ酸塩、α−オレフィンスルホン酸塩、アルキル硫酸塩などが好適に用いられる。発泡性および耐硬水性の点で、ラウロイルサルコシンナトリウム、アルキル鎖の炭素鎖長として炭素数が10〜16のα−オレフィンスルホン酸ナトリウム、ラウリル硫酸ナトリウムなどが好適に用いられる。 Examples of the anionic surfactant include N-acyl amino acid salt, α-olefin sulfonate, N-acyl sulfonate, alkyl sulfate, glycerol fatty acid ester sulfate, lauroyl sarcosine sodium, and alkyl chain carbon chain. Examples of the length include sodium α-olefin sulfonate and sodium lauryl sulfate having 10 to 16 carbon atoms. From the viewpoint of versatility, N-acyl amino acid salts, α-olefin sulfonates, alkyl sulfates and the like are preferably used. From the viewpoint of foamability and hard water resistance, sodium lauroyl sarcosine, sodium α-olefin sulfonate having a carbon number of 10 to 16 as the carbon chain length of the alkyl chain, sodium lauryl sulfate and the like are preferably used.
ノニオン性界面活性剤としては、例えば、ポリオキシエチレンアルキルエーテル、ポリオキシエチレン−ポリオキシプロピレンブロック共重合体、ポリオキシエチレン硬化ヒマシ油、グリセリンエステルのポリオキシエチレンエーテル、ショ糖脂肪酸エステル、アルキロールアミドなどが挙げられる。汎用性の点で、ポリオキシエチレンアルキルエーテル、ポリオキシエチレン硬化ヒマシ油、アルキロールアミド、ソルビタン脂肪酸エステルなどが好適に用いられる。具体的には、アルキル鎖の炭素鎖長として炭素数が14〜18で、エチレンオキサイド平均付加モル数が15〜30のポリオキシエチレンアルキルエーテル、エチレンオキサイド平均付加モル数が40〜100のポリオキシエチレン硬化ヒマシ油、アルキル鎖の炭素鎖長として炭素数が12〜14のアルキロールアミド、脂肪酸の炭素数が12〜18のソルビタン脂肪酸エステル、脂肪酸の炭素数が16〜18でエチレンオキサイド平均付加モル数が10〜40のポリオキシエチレンソルビタン脂肪酸エステル等を使用できる。 Nonionic surfactants include, for example, polyoxyethylene alkyl ether, polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene hydrogenated castor oil, glycerin ester polyoxyethylene ether, sucrose fatty acid ester, alkylol Examples include amides. From the viewpoint of versatility, polyoxyethylene alkyl ether, polyoxyethylene hydrogenated castor oil, alkylolamide, sorbitan fatty acid ester and the like are preferably used. Specifically, the carbon chain length of the alkyl chain is 14 to 18 carbon atoms, polyoxyethylene alkyl ether having an ethylene oxide average addition mole number of 15 to 30, and polyoxyethylene having an ethylene oxide average addition mole number of 40 to 100. Ethylene hardened castor oil, alkylolamide having 12 to 14 carbon atoms as carbon chain length of alkyl chain, sorbitan fatty acid ester having 12 to 18 carbon atoms of fatty acid, ethylene oxide average addition mole with 16 to 18 carbon atoms of fatty acid A polyoxyethylene sorbitan fatty acid ester having a number of 10 to 40 can be used.
粘結剤としては、例えば、プルラン、ゼラチン、カルボキシメチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、キサンタンガム、アラビアガム、グアーガム、ローカストビーンガム、ポリビニルアルコール、ポリビニルピロリドン、ポリアクリル酸ナトリウム、アルギン酸ナトリウム等が挙げられる。粘結剤は、1種を用いても良いし、2種以上の組み合わせを用いてもよい。粘結剤の配合量は、通常、組成物全体に対して0.01〜2質量%である。 Examples of the binder include pullulan, gelatin, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, xanthan gum, gum arabic, guar gum, locust bean gum, polyvinyl alcohol, polyvinylpyrrolidone, sodium polyacrylate, sodium alginate. Etc. As the binder, one type may be used, or a combination of two or more types may be used. The compounding quantity of a binder is 0.01-2 mass% normally with respect to the whole composition.
粘稠剤としては、例えば、プロピレングリコール、ブチレングリコール、グリセリン、ソルビトール、ポリエチレングリコール等が挙げられ、通常、製剤全体に対して1〜50質量%配合することができる。 Examples of the thickening agent include propylene glycol, butylene glycol, glycerin, sorbitol, polyethylene glycol, and the like, and usually 1 to 50% by mass can be added to the whole preparation.
甘味剤としては、例えば、サッカリンナトリウム、ステビオサイド、ネオヘスペリジンヒドロカルコン、グリチルリチン、ペリラルチン、p−メトキシシンナミックアルデヒド、ソーマチン、キシリトール、パラチノース、マルチトール等が挙げられる。 Examples of the sweetening agent include saccharin sodium, stevioside, neohesperidin hydrochalcone, glycyrrhizin, perilartine, p-methoxycinnamamic aldehyde, thaumatin, xylitol, palatinose, maltitol and the like.
防腐剤としては、例えば、安息香酸ナトリウム、パラオキシ安息香酸エステル、メチルパラベン、エチルパラベン、ブチルパラベン、エチレンジアミン四酢酸塩、塩化ベンザルコニウム等が挙げられる。 Examples of the preservative include sodium benzoate, paraoxybenzoate ester, methyl paraben, ethyl paraben, butyl paraben, ethylenediamine tetraacetate, benzalkonium chloride and the like.
研磨剤としては、無水ケイ酸、水酸化アルミニウム、第2リン酸カルシウム2水和物及び無水物、第1リン酸カルシウム、第3リン酸カルシウム、炭酸カルシウム、ピロリン酸カルシウム、酸化チタン、アルミナ、水和アルミナ、沈降性シリカ、その他のシリカ系研磨剤、ケイ酸アルミニウム、不溶性メタリン酸ナトリウム、不溶性メタリン酸カリウム、第3リン酸マグネシウム、炭酸マグネシウム、硫酸カルシウム、ベントナイト、ケイ酸ジルコニウム、合成樹脂等が例示され、これらの1種又は2種以上を使用することができる。 As abrasives, anhydrous silicic acid, aluminum hydroxide, dibasic calcium phosphate dihydrate and anhydride, primary calcium phosphate, tertiary calcium phosphate, calcium carbonate, calcium pyrophosphate, titanium oxide, alumina, hydrated alumina, precipitated silica Other silica-based abrasives, aluminum silicate, insoluble sodium metaphosphate, insoluble potassium metaphosphate, tertiary magnesium phosphate, magnesium carbonate, calcium sulfate, bentonite, zirconium silicate, synthetic resin, etc. Species or two or more can be used.
香料としては、例えば、以下のものが挙げられる:ペパーミント、スペアミント等の精油;レモン、ストロベリー等のフルーツ系のエッセンス;1−メントール、カルボン、オイゲノール、アネトール、リナロール、リモネン、オシメン、シネオール、n−デシルアルコール、シトロネロール、ワニリン、α−テルピネオール、サリチル酸メチル、チモール、ローズマリー油、セージ油、シソ油、レモン油、オレンジ油等の香料素材。 Examples of the fragrance include the following: essential oils such as peppermint and spearmint; fruit-based essences such as lemon and strawberry; 1-menthol, carvone, eugenol, anethole, linalool, limonene, ocimen, cineole, n- Fragrance materials such as decyl alcohol, citronellol, vanillin, α-terpineol, methyl salicylate, thymol, rosemary oil, sage oil, perilla oil, lemon oil and orange oil.
薬用成分としては、例えば、以下のものが挙げられる:クロロヘキシジン、トリクロサン、イソプロピルメチルフェノール、塩化セチルピリジニウム、グルコン酸亜鉛、クエン酸亜鉛等の殺菌又は抗菌剤;縮合リン酸塩、エタンヒドロキシジホスフォネート等の歯石予防剤;トラネキサム酸、グリチルリチン2カリウム塩、ε−アミノカプロン酸等の抗炎症剤;ヒドロキシエチルセルロースジメチルジアリルアンモニウムクロリド等のコーティング剤;デキストラナーゼ、ムタナーゼ等の酵素剤。薬用成分の配合量は、薬剤学的に許容できる範囲で調整することができる。 Examples of medicinal ingredients include: bactericidal or antibacterial agents such as chlorohexidine, triclosan, isopropylmethylphenol, cetylpyridinium chloride, zinc gluconate, zinc citrate; condensed phosphates, ethane hydroxydiphospho Calculus preventive agents such as nates; anti-inflammatory agents such as tranexamic acid, glycyrrhizin dipotassium salt and ε-aminocaproic acid; coating agents such as hydroxyethylcellulose dimethyldiallylammonium chloride; enzyme agents such as dextranase and mutanase. The amount of the medicinal component can be adjusted within a pharmaceutically acceptable range.
溶媒(溶剤)としては、例えば、水、エタノール等が挙げられる。 Examples of the solvent (solvent) include water and ethanol.
本発明の口腔用組成物の剤型としては、例えば、歯磨組成物(例:練歯磨、潤製歯磨、粉歯磨、液状歯磨、液体歯磨、水歯磨)、マウスウォッシュ、洗口組成物、口腔用貼付組成物などの各種形態が挙げられる。これらのうち、有効性および安定性の観点から、歯磨組成物、洗口組成物が好ましい。本発明の口腔用組成物の形態は特に限定されるものではなく、例えば、液状、固形状、ペースト状、ゲル状などが挙げられる。 Examples of the dosage form of the oral composition of the present invention include a dentifrice composition (e.g., toothpaste, toothpaste, powder dentifrice, liquid dentifrice, liquid dentifrice, water dentifrice), mouthwash, mouthwash composition, oral cavity, and the like. Various forms such as a patch composition for use. Of these, a dentifrice composition and a mouthwash composition are preferable from the viewpoints of effectiveness and stability. The form of the composition for oral cavity of the present invention is not particularly limited, and examples thereof include liquid, solid, paste, and gel.
本発明の口腔用組成物のpHは、有効性および安定性の観点から、下限は6以上であることが好ましい。上限は8.5以下であることが好ましい。pHは6〜8.5であることが好ましい。本発明の口腔用組成物は、必要に応じてpH調整剤を含んでいてもよい。pH調整剤としては、例えば、リン酸又はその塩(例えば、リン酸ナトリウム、リン酸水素ナトリウムなど)、クエン酸又はその塩(例えば、クエン酸ナトリウムなど)、リンゴ酸又はその塩、グルコン酸又はその塩、マレイン酸又はその塩、コハク酸又はその塩、グルタミン酸又はその塩、乳酸、塩酸、酢酸、硝酸、水酸化ナトリウム、水酸化カリウムなどが挙げられる。pH調整剤の配合量は、本発明の効果を損なわない範囲で調整することができる。 The lower limit of the pH of the oral composition of the present invention is preferably 6 or more from the viewpoints of effectiveness and stability. The upper limit is preferably 8.5 or less. The pH is preferably 6 to 8.5. The composition for oral cavity of this invention may contain the pH adjuster as needed. Examples of the pH adjuster include phosphoric acid or a salt thereof (for example, sodium phosphate, sodium hydrogenphosphate and the like), citric acid or a salt thereof (for example, sodium citrate), malic acid or a salt thereof, gluconic acid or The salt, maleic acid or its salt, succinic acid or its salt, glutamic acid or its salt, lactic acid, hydrochloric acid, acetic acid, nitric acid, sodium hydroxide, potassium hydroxide, etc. are mentioned. The compounding quantity of a pH adjuster can be adjusted in the range which does not impair the effect of this invention.
本発明の口腔用組成物のヒトへの適用量の例を挙げると、1日あたり3回適用する場合に、1回の使用量を0.5〜2g、好ましくは約0.5〜1gの量で適宜調整することができる。 When the example of the application amount to the human of the composition for oral cavity of this invention is given, when applying 3 times per day, the usage-amount of 1 time is 0.5-2g, Preferably it is about 0.5-1g. The amount can be adjusted as appropriate.
本発明の口腔用組成物は、象牙質表面に無機質を沈着させ、象牙質が露出していた部分をエナメル質に近い状態とするため、知覚過敏を顕著に抑制することができる。従来の知覚過敏抑制用の口腔用組成物(例えば、乳酸アルミニウムや硝酸カリウム塩)では、知覚過敏の抑制効果はごく一時的なものであったのに対し、本発明の口腔用組成物は、知覚過敏を顕著に抑制することができるだけでなく、持続的な抑制効果を発揮することができる。よって、本発明の口腔用組成物は、知覚過敏抑制組成物と言い換えることもでき、知覚過敏症の症状緩和のために有用である。 Since the composition for oral cavity of this invention deposits an inorganic substance on the dentine surface and makes the part which dentin exposed the state close to an enamel, it can suppress hypersensitivity notably. In conventional oral compositions for suppressing hypersensitivity (for example, aluminum lactate and potassium nitrate), the effect of suppressing hypersensitivity was very temporary, whereas the oral composition of the present invention is Not only can hypersensitivity be remarkably suppressed, but also a sustained suppression effect can be exhibited. Therefore, the composition for oral cavity of the present invention can be rephrased as a composition for suppressing hypersensitivity and is useful for alleviating symptoms of hypersensitivity.
また、本発明の口腔用組成物は、上記の通り露出象牙質をエナメル質に近い状態にするため、根面う蝕を含む象牙質う蝕を顕著に予防することができる。これにより、象牙質の硬さを向上させることができると共に、象牙質の耐酸性を向上させることができる。よって、本発明の口腔用組成物は、象牙質の耐酸性向上組成物、または象牙質の硬さ向上組成物と言い換えることもでき、象牙質う蝕、特に根面う蝕の予防のために有用である。 Moreover, since the composition for oral cavity of this invention makes exposed dentine the state close | similar to enamel as above-mentioned, it can prevent dentin caries including root caries remarkably. Thereby, while being able to improve the hardness of dentin, the acid resistance of dentin can be improved. Therefore, the composition for oral cavity of the present invention can be rephrased as a dentin acid resistance improving composition or a dentin hardness improving composition for the prevention of dentine caries, particularly root caries. Useful.
さらに本発明の組成物は、可溶性フッ化物を安定に保持しているので、フッ素本来の機能である耐酸性の向上機能、再石灰化促進機能、歯垢細菌の酵素作用機能が発揮され、う蝕予防効果を顕著に発揮することができる。また、可溶性フッ化物の安定性も、上記知覚過敏の抑制および象牙質の硬さ向上ならびに耐酸性向上に寄与しているものと推測される。さらに、本発明の組成物における(A)と(C)とは、組成物中の可溶性フッ素化合物の安定性を向上させる役割を有していると考えられ、(A)と(C)とを、フッ素化合物を含む本発明以外の口腔用組成物に添加すれば、該組成物中の可溶性フッ素化合物の安定性の向上効果を得ることができると推測される。よって、本発明は、(A)と(C)とを含有する、フッ素化合物を含む口腔用組成物用の、可溶性フッ素化合物の安定性向上組成物として応用することができる。 Further, since the composition of the present invention stably retains soluble fluoride, the function of improving acid resistance, the function of promoting remineralization, and the function of enzymatic action of plaque bacteria, which are the original functions of fluorine, are exhibited. The anti-eating effect can be remarkably exhibited. In addition, it is estimated that the stability of the soluble fluoride also contributes to the suppression of the above-mentioned hypersensitivity, the dentin hardness and the acid resistance. Further, (A) and (C) in the composition of the present invention are considered to have a role of improving the stability of the soluble fluorine compound in the composition, and (A) and (C) If it is added to an oral composition other than the present invention containing a fluorine compound, it is presumed that the effect of improving the stability of the soluble fluorine compound in the composition can be obtained. Therefore, the present invention can be applied as a composition for improving the stability of a soluble fluorine compound for an oral composition containing a fluorine compound containing (A) and (C).
本発明の口腔用組成物は、(C)成分や、(A)〜(C)以外の他の成分に由来する金属味や苦味が改善されているので、上記の諸効果とあいまって歯磨組成物、洗口組成物などの口腔用組成物としてきわめて有用である。 Since the oral taste composition of the present invention has improved metallic taste and bitterness derived from the component (C) and other components other than (A) to (C), the toothpaste composition combined with the above effects It is extremely useful as a composition for oral cavity such as a product and a mouthwash composition.
〔原料〕
以下の実施例にて使用した原料は、以下の通りである。
〔material〕
The raw materials used in the following examples are as follows.
(A−1):乳清
・FMエキスLA(一丸ファルコス(株)製、乳清固形分実濃度:7質量%)
・ホエイパウダーDX(森永乳業(株)製、乳清固形分実濃度:96質量%)
(A−2):ラクトフェリン
・ラクトフェリンEX(森永乳業(株)製、ラクトフェリン固形分実濃度:100質量%)
(A-1): Whey FM Extract LA (Ichimaru Falcos Co., Ltd., whey solid content concentration: 7% by mass)
・ Whey powder DX (manufactured by Morinaga Milk Industry Co., Ltd., whey solid content concentration: 96 mass%)
(A-2): Lactoferrin-Lactoferrin EX (Morinaga Milk Industry Co., Ltd., actual concentration of lactoferrin solid content: 100% by mass)
(B):フッ素化合物
・フッ化ナトリウム(ステラケミファ(株)製)
・モノフルオロリン酸ナトリウム(ローディア日華(株)製)
(B): Fluorine compound Sodium fluoride (manufactured by Stella Chemifa Corporation)
・ Sodium monofluorophosphate (manufactured by Rhodia Nikka Co., Ltd.)
(C):塩類
・硝酸カリウム(和光純薬工業(株)製)
・硝酸ナトリウム(和光純薬工業(株)製)
・塩化ナトリウム(和光純薬工業(株)製)
・塩化カリウム(和光純薬工業(株)製)
・硫酸ナトリウム(和光純薬工業(株)製)
・リン酸二水素カリウム(和光純薬(株)製)
(C): Salts · Potassium nitrate (Wako Pure Chemical Industries, Ltd.)
・ Sodium nitrate (Wako Pure Chemical Industries, Ltd.)
・ Sodium chloride (Wako Pure Chemical Industries, Ltd.)
・ Potassium chloride (manufactured by Wako Pure Chemical Industries, Ltd.)
・ Sodium sulfate (manufactured by Wako Pure Chemical Industries, Ltd.)
・ Potassium dihydrogen phosphate (Wako Pure Chemical Industries, Ltd.)
(D):その他
・キシリトール(ロケット・フルーレ製)
(D): Other ・ Xylitol (Rocket Fleure)
実施例1〜37および比較例1〜11〔練歯磨組成物の調製〕
表1−1〜1−5に示す各組成の練歯磨組成物を、以下のようにして調製した。
Examples 1-37 and Comparative Examples 1-11 [Preparation of a toothpaste composition]
The toothpaste compositions having the compositions shown in Tables 1-1 to 1-5 were prepared as follows.
精製水中に、水溶成分(乳清、ラクトフェリン、フッ化ナトリウム、モノフルオロリン酸ナトリウム、硝酸カリウム、硝酸ナトリウム、サッカリンナトリウム、70質量%ソルビトール等)を常温で混合溶解させ、A相を調製した。プロピレングリコール中に、殺菌剤、防腐剤(メチルパラベン等)等の油溶性成分、ポリアクリル酸ナトリウム、アルギン酸ナトリウム等の粘結剤を常温で溶解し分散させ、B相を調製した。次に、撹拌中のA相の中にB相を添加混合し、C相を調製した。C相中に、香料、無水ケイ酸、その他の成分(ラウリル硫酸ナトリウム、水酸化ナトリウム等)を、1.5Lニーダー(石山工作所製)を用い常温で混合し、4kPaまで減圧し脱泡を行い、練歯磨組成物1.0kgを得た。 A phase A was prepared by mixing and dissolving water-soluble components (whey, lactoferrin, sodium fluoride, sodium monofluorophosphate, potassium nitrate, sodium nitrate, sodium saccharin, 70 mass% sorbitol, etc.) in purified water at room temperature. In propylene glycol, oil-soluble components such as bactericides and preservatives (such as methylparaben) and binders such as sodium polyacrylate and sodium alginate were dissolved and dispersed at room temperature to prepare Phase B. Next, B phase was added and mixed in A phase under stirring, and C phase was prepared. In Phase C, fragrance, anhydrous silicic acid, and other ingredients (sodium lauryl sulfate, sodium hydroxide, etc.) are mixed at room temperature using a 1.5 L kneader (manufactured by Ishiyama Kogakusho), depressurized to 4 kPa and degassed. This was done to obtain 1.0 kg of a toothpaste composition.
〔実験例1.可溶性フッ素化合物の安定性試験〕
上記実施例および比較例の練歯磨組成物を50mLのポリプロピレン製の透明容器に充填し、50℃で1ヶ月保存した。
[Experimental Example 1. (Stability test of soluble fluorine compound)
The toothpaste compositions of the above examples and comparative examples were filled in a 50 mL transparent container made of polypropylene and stored at 50 ° C. for 1 month.
1ヶ月保存後の各充填物の全量を、よく撹拌後、その10mLを別のポリプロピレン製の遠沈菅に採取し、遠心機(国産遠心機株式会社製、H−103N)にて室温1500×g、10分間遠心した。 After thoroughly agitating the total amount of each packing after storage for 1 month, 10 mL thereof was collected in another polypropylene centrifuge, and the room temperature was 1500 × using a centrifuge (manufactured by Kokusan Centrifuge Co., Ltd., H-103N). g Centrifuge for 10 minutes.
遠心後、モノフルオロリン酸ナトリウムを含有しない実施例及び比較例については、上記遠心後の上清液1mLを10mLメスフラスコに注意深く採取し、pH5.5の1Mクエン酸カリウム緩衝液を5mL加え、被験液とした。最後に蒸留水で10mLにメスアップし、フッ素イオンメーター(ORION社製、EA−920)にて被験液中の可溶性フッ素イオン濃度(C1M)を測定した。 After centrifugation, for Examples and Comparative Examples that do not contain sodium monofluorophosphate, carefully extract 1 mL of the supernatant after centrifugation into a 10 mL volumetric flask, add 5 mL of 1M potassium citrate buffer at pH 5.5, A test solution was used. Finally, the volume was made up to 10 mL with distilled water, and the soluble fluoride ion concentration (C 1M ) in the test solution was measured with a fluoride ion meter (ORION, EA-920).
モノフルオロリン酸ナトリウムを含有する実施例及び比較例については、上記遠心後の上清液1mLを3mLのねじ口テフロン(登録商標)チューブに注意深く採取し、2規定硫酸1mLを加えて密栓した。その後、10分間煮沸し加水分解させた。冷却後、加水分解させた液1mLを10mLメスフラスコに注意深く採取し、pH5.5の1mol/Lクエン酸カリウム緩衝液を5mL加え被験液とした。最後に蒸留水で10mLにメスアップし、フッ素イオンメーター(ORION社製、EA−920)にて被験液中の可溶性フッ化物イオン濃度(1ヶ月保存後の可溶性フッ化物イオン濃度、C1M)を測定した。 For Examples and Comparative Examples containing sodium monofluorophosphate, 1 mL of the supernatant after centrifugation was carefully collected in a 3 mL screw-teflon Teflon (registered trademark) tube, and 1 mL of 2N sulfuric acid was added and sealed. Then, it was boiled for 10 minutes and hydrolyzed. After cooling, 1 mL of the hydrolyzed solution was carefully collected in a 10 mL volumetric flask, and 5 mL of 1 mol / L potassium citrate buffer solution with pH 5.5 was added to prepare a test solution. Finally, the volume is made up to 10 mL with distilled water, and the soluble fluoride ion concentration in the test solution (soluble fluoride ion concentration after storage for 1 month, C 1M ) is measured with a fluoride ion meter (ORION, EA-920). It was measured.
調製直後の各充填物についても、上記1ヶ月保存後の各充填物と同様に、被験液を調製し被験液中の可溶性フッ化物イオン濃度(調製直後の可溶性フッ化物イオン濃度、C0)を測定した。各実施例および比較例について、調製直後と比較した1ヶ月保存後の可溶性フッ化物イオンの残存率(%)を、以下の式(1)で求めた。 For each filling immediately after preparation, similarly to each filling after the above-mentioned storage for 1 month, a test solution is prepared and the soluble fluoride ion concentration in the test solution (soluble fluoride ion concentration immediately after preparation, C 0 ) is determined. It was measured. For each of the examples and comparative examples, the residual ratio (%) of soluble fluoride ions after storage for 1 month compared with immediately after preparation was determined by the following formula (1).
〔式(1)〕
可溶性フッ化物イオンの残存率(%)=(C0−C1M)/C0×100
[Formula (1)]
Residual rate of soluble fluoride ion (%) = (C 0 −C 1M ) / C 0 × 100
下記評価基準1により、式(1)にて算出された可溶性フッ化物イオンの残存率を実施例および比較例ごとに評価し、表1−1〜1−5に示した。 According to the following evaluation criteria 1, the residual ratio of soluble fluoride ions calculated by the formula (1) was evaluated for each of Examples and Comparative Examples and shown in Tables 1-1 to 1-5.
〔評価基準1〕
◎:可溶性フッ化物イオンの残存率が90%以上である
○:可溶性フッ化物イオンの残存率が80%以上90%未満である
△:可溶性フッ化物イオンの残存率が60%以上80%未満である
×:可溶性フッ化物イオンの残存率が60%未満である
[Evaluation criteria 1]
◎: Residual rate of soluble fluoride ions is 90% or more ○: Residual rate of soluble fluoride ions is 80% or more and less than 90% Δ: Residual rate of soluble fluoride ions is 60% or more and less than 80% Yes x: Residual rate of soluble fluoride ion is less than 60%
表1−1〜1−5から明らかなとおり、実施例の練歯磨組成物の評価は、比較例の練歯磨組成物の評価と比較して優れていた。この結果は、本発明の口腔用組成物においては、(B)であるフッ素化合物が他の成分と反応することなく、可溶性フッ素化合物として安定して存在しており、フッ素化合物によるう蝕予防効果を効率的に発揮できることを示す。 As is clear from Tables 1-1 to 1-5, the evaluation of the toothpaste compositions of the examples was superior to the evaluation of the toothpaste compositions of the comparative examples. As a result, in the oral composition of the present invention, the fluorine compound (B) is stably present as a soluble fluorine compound without reacting with other components. It is shown that can be demonstrated efficiently.
〔実験例2.知覚過敏の抑制効果(象牙細管の狭窄および閉塞効果)〕
上記のごとく調製した組成物を用いて、Pashleyらの方法(J.Dent.Res.57,187−193,1978)に準じ、象牙細管の液の通過量を計測し、各実施例の練歯磨組成物処理による象牙細管の狭窄および閉塞の程度を評価した。
[Experimental Example 2. Inhibition of hypersensitivity (stenosis and occlusion of dentinal tubules)
Using the composition prepared as described above, according to the method of Pashley et al. (J. Dent. Res. 57, 187-193, 1978), the amount of liquid passing through the dentinal tubule was measured, and the toothpaste of each example. The degree of stenosis and occlusion of dentinal tubules by the composition treatment was evaluated.
ヒト大臼歯の歯冠部より厚み1mmの象牙質ディスクを切り出し、耐水研磨紙#2000で研磨を行ない、さらに50質量%クエン酸水溶液でエッチングし、象牙細管を開口させたものをサンプルとした。このサンプルに対し、各実施例および比較例の練歯磨組成物10gと、1mM相当のCaCl2、3mM相当のKH2PO4および1.0単位/mLの酸性フォスファターゼを含むpH7.0の人工唾液20gとを、混合し、3倍希釈液とし、これを処置液とした。なお、3倍希釈は、歯磨き時に練歯磨組成物が唾液によって3倍に希釈されることを想定したことによる。この処置液にサンプルを3分間浸漬し、蒸留水で軽くすすいだ後、余分な処置液を除去し、上記人工唾液中に37℃で12時間浸漬した。同様の操作を1日2回行ない、この一連の操作を合計5日間繰り返した。さらに、各サンプルを3分間生理食塩水に浸漬した後、20秒間の水ブラッシングを行う操作を、20回繰り返した。終了後、サンプルを蒸留水でよく濯ぎ、水分を切った後装置に固定し一定圧下で5分間生理食塩水を流し、サンプルを通過する単位時間(5分間)当たりの生理食塩水の量を測定した。各実施例および比較例の練歯磨組成物を含む処置液による、上記処置後の象牙細管の液の通過量と、処置前の通過量とを、式(2)に代入して、各実施例および比較例ごとの通過性抑制率を算出した。式(2)で示される通過性抑制率は、大きいほど、処置後の象牙細管の狭窄および閉塞の程度が高いことを示す。 A 1 mm thick dentin disc was cut out from the crown of a human molar tooth, polished with water-resistant abrasive paper # 2000, etched with a 50% by mass citric acid aqueous solution, and a dentinal tubule was opened as a sample. For this sample, artificial saliva of pH 7.0 containing 10 g of each toothpaste composition of each example and comparative example, 1 mM equivalent CaCl 2 , 3 mM equivalent KH 2 PO 4 and 1.0 unit / mL acid phosphatase. 20 g was mixed to obtain a 3-fold diluted solution, which was used as a treatment solution. The 3-fold dilution is based on the assumption that the toothpaste composition is diluted 3-fold with saliva when brushing. The sample was immersed in this treatment solution for 3 minutes, rinsed lightly with distilled water, then the excess treatment solution was removed, and immersed in the artificial saliva at 37 ° C. for 12 hours. The same operation was performed twice a day, and this series of operations was repeated for a total of 5 days. Furthermore, after immersing each sample in physiological saline for 3 minutes, the operation of performing water brushing for 20 seconds was repeated 20 times. After completion, rinse the sample thoroughly with distilled water, drain the water, fix it on the device, and flow physiological saline under constant pressure for 5 minutes, and measure the amount of physiological saline per unit time (5 minutes) passing through the sample did. By substituting the passage amount of the dentinal tubule after the treatment and the passage amount before the treatment with the treatment liquid containing the toothpaste composition of each Example and Comparative Example into the formula (2), each Example And the permeability suppression rate for every comparative example was calculated. It shows that the degree of stenosis and occlusion of a dentinal tubule after a treatment is so high that the permeability | blocking suppression rate shown by Formula (2) is large.
〔式(2)〕
通過性抑制率(%)=
(処置前の通過量−処置後の通過量)/処置前の通過量×100
[Formula (2)]
Passability suppression rate (%) =
(Passage before treatment-Passage after treatment) / Passage before treatment x 100
下記評価基準2により、式(2)で算出された通過性抑制率を実施例および比較例ごとに評価し、表1−1〜1−5に示した。なお、一連の実験操作は、各実施例および比較例につきN=5で行ない、評価基準2による評価には、通過性抑制率の平均値を採用した。 According to the following evaluation criteria 2, the permeability suppression rate calculated by the formula (2) was evaluated for each of Examples and Comparative Examples, and shown in Tables 1-1 to 1-5. Note that a series of experimental operations were performed at N = 5 for each example and comparative example, and the average value of the passability suppression rate was adopted for the evaluation based on the evaluation criterion 2.
〔評価基準2〕
◎:通過性抑制率が90%以上である
○:通過性抑制率が80%以上90%未満である
△:通過性抑制率が60%以上80%未満である
×:通過性抑制率が60%未満である
[Evaluation criteria 2]
A: The permeability inhibition rate is 90% or more. O: The permeability inhibition rate is 80% or more and less than 90%. Δ: The permeability inhibition rate is 60% or more and less than 80%. X: The permeability inhibition rate is 60. Less than%
表1−1〜1−5から明らかなとおり、実施例の練歯磨組成物の評価は、比較例の練歯磨組成物の評価と比較して優れていた。中でも、比較例の、従来の知覚過敏抑制剤に相当する比較例11(乳酸アルミニウム)では象牙細管の封鎖は不十分であり、比較例2および5(硝酸カリウム)では、象牙細管を全く封鎖することができていなかったのに対し、実施例の練歯磨組成物で処理したサンプルでは、象牙細管が効果的に石灰化封鎖してエナメル質様となっていた。このことは、本発明の口腔用組成物が、知覚過敏を持続的に抑制し症状を顕著に緩和できることを示す。 As is clear from Tables 1-1 to 1-5, the evaluation of the toothpaste compositions of the examples was superior to the evaluation of the toothpaste compositions of the comparative examples. Among them, in Comparative Example 11 (aluminum lactate) corresponding to a conventional hypersensitivity inhibitor of Comparative Example, dentinal tubules are not sufficiently sealed, and in Comparative Examples 2 and 5 (potassium nitrate), dentinal tubules are completely blocked. On the other hand, in the sample treated with the toothpaste composition of the example, the dentinal tubule was effectively calcified and sealed to become enamel-like. This shows that the composition for oral cavity of the present invention can suppress hypersensitivity continuously and relieve symptoms remarkably.
〔実験例3.象牙質耐酸性の評価〕
根面う蝕予防効果の第一の確認実験として、象牙質の化学的強度(耐酸性)変化を評価した。具体的には、以下の通りである。
[Experimental Example 3. Dentin acid resistance evaluation)
As the first confirmation experiment of the root caries prevention effect, the chemical strength (acid resistance) change of dentin was evaluated. Specifically, it is as follows.
牛歯根から、表面に2mm×2mmのウィンドウを施した象牙質ブロックを作製した。実験例2と同様に、各実施例および比較例の練歯磨組成物を、人工唾液で希釈した処理液に浸漬させた。具体的には、各実施例および比較例の練歯磨組成物10gと、1mM相当のCaCl2、3mM相当のKH2PO4および1.0単位/mLの酸性フォスファターゼを含むpH7.0の人工唾液20gとを混合し、3倍希釈液とし、これを処置液とした。この処置液にサンプルを3分間浸漬し、蒸留水で軽くすすいだ後、余分な処置液を除去し上記人工唾液中に37℃で12時間浸漬した。同様の操作を1日2回行ない、この一連の操作を合計5日間繰り返した。 A dentin block having a 2 mm × 2 mm window on the surface was prepared from the bovine root. Similarly to Experimental Example 2, the toothpaste compositions of each Example and Comparative Example were immersed in a treatment solution diluted with artificial saliva. Specifically, artificial saliva of pH 7.0 containing 10 g of the toothpaste compositions of each Example and Comparative Example, 1 mM equivalent CaCl 2 , 3 mM equivalent KH 2 PO 4 and 1.0 unit / mL acid phosphatase. 20 g was mixed to obtain a 3-fold diluted solution, which was used as a treatment solution. The sample was immersed in this treatment solution for 3 minutes, rinsed lightly with distilled water, then the excess treatment solution was removed and immersed in the artificial saliva at 37 ° C. for 12 hours. The same operation was performed twice a day, and this series of operations was repeated for a total of 5 days.
最終日に、サンプルを蒸留水でよく濯ぎ水分を切った後、このサンプルを、CaCl2:2.2mM、KH2PO4:2.2mMおよび酢酸:100mMを含む、pH4.5の脱灰液に、37℃、6時間浸漬した。6時間後、各脱灰液中に溶出したカルシウムイオン濃度を原子吸光光度計(日立Z−5310、日立ハイテクノロジーズ製)にて測定し、各象牙質ブロックの脱灰程度(各実施例および比較例の溶出Ca量)を評価した。処置液への浸漬を行わずに、人工唾液への浸漬のみを行ったほかは同様の処理を行った比較サンプルを用意し、比較サンプルについての脱灰液中に溶出したカルシウムイオン量(μg)を同様に測定し、これを基準脱灰量(N=3での平均溶出Ca量)とした。 On the last day, after thoroughly rinsing the sample with distilled water and draining the water, the sample was decalcified at pH 4.5 containing CaCl 2 : 2.2 mM, KH 2 PO 4 : 2.2 mM and acetic acid: 100 mM. The sample was soaked at 37 ° C. for 6 hours. After 6 hours, the calcium ion concentration eluted in each decalcification solution was measured with an atomic absorption photometer (Hitachi Z-5310, manufactured by Hitachi High-Technologies), and the degree of demineralization of each dentin block (each example and comparison) Example elution Ca amount) was evaluated. Prepare a comparative sample with the same treatment except that it was immersed in artificial saliva without being immersed in the treatment solution, and the amount of calcium ions eluted in the decalcification solution for the comparative sample (μg) Was measured in the same manner as a reference decalcification amount (average amount of eluted Ca at N = 3).
各実施例および比較例の溶出Ca量および基準脱灰量を、下記式(3)に代入して、象牙質脱灰抑制率を算出した。 The elution Ca amount and the reference decalcification amount of each example and comparative example were substituted into the following formula (3) to calculate the dentin demineralization inhibition rate.
〔式(3)〕
象牙質脱灰抑制率(%)=
((基準脱灰量)−(実施例又は比較例の溶出Ca量))/基準脱灰量×100
[Formula (3)]
Dentin demineralization inhibition rate (%) =
((Reference decalcification amount) − (elution Ca amount of examples or comparative examples)) / reference decalcification amount × 100
下記評価基準3により、上記式(3)で算出される象牙質脱灰抑制率から、実施例および比較例の練歯磨組成物を含む処置液による、上記処置後の象牙質耐酸性の向上の程度を評価し、表1−1〜1−5に示した。なお一連の実験操作は、各実施例及び比較例につきN=3で行ない、評価基準3による評価には脱灰抑制率の平均値を採用した。 From the dentin demineralization inhibition rate calculated by the above formula (3) according to the following evaluation criteria 3, the treatment solution containing the toothpaste compositions of Examples and Comparative Examples improves the dentin acid resistance after the treatment. The degree was evaluated and shown in Tables 1-1 to 1-5. In addition, a series of experiment operation was performed by N = 3 for each Example and the comparative example, and the average value of the demineralization suppression rate was employ | adopted for evaluation by the evaluation criteria 3. FIG.
〔評価基準3〕
◎:象牙質脱灰抑制率が50%以上
○:象牙質脱灰抑制率が30%以上50%未満
△:象牙質脱灰抑制率が20%以上30%未満
×:象牙質脱灰抑制率が20%未満
[Evaluation criteria 3]
◎: Dentin demineralization inhibition rate is 50% or more ○: Dentin demineralization inhibition rate is 30% or more and less than 50% Δ: Dentin demineralization inhibition rate is 20% or more and less than 30% ×: Dentin demineralization inhibition rate Is less than 20%
表1−1〜1−5から明らかなとおり、実施例の練歯磨組成物の評価は、比較例の練歯磨組成物の評価と比較して優れていた。この結果は、本発明の口腔用組成物が、象牙質表面に無機質を沈着させ、象牙細管を封鎖し脱灰を抑制する作用を有し、これにより象牙質が露出していた部分をエナメル質に近い状態として、象牙質の耐酸性を顕著に向上させることができることを示す。 As is clear from Tables 1-1 to 1-5, the evaluation of the toothpaste compositions of the examples was superior to the evaluation of the toothpaste compositions of the comparative examples. As a result, the composition for oral cavity of the present invention has an action of depositing an inorganic substance on the surface of the dentin, sealing the dentinal tubule and suppressing decalcification, and thereby the portion where the dentin is exposed is enamel. It shows that the acid resistance of dentin can be remarkably improved as a state close to.
〔実験例4.象牙質硬さ向上効果の評価〕
根面う蝕予防効果の第二の確認実験として、象牙質の物理的強度(硬さ)の変化を評価した。具体的には、以下の通りである。
[Experimental Example 4. Evaluation of dentin hardness improvement effect)
As a second confirmation experiment of the root caries prevention effect, changes in physical strength (hardness) of dentin were evaluated. Specifically, it is as follows.
ヒト大臼歯の歯冠部より厚み1mmの象牙質ディスクを切り出し、耐水研磨紙#4000で研磨を行なった。さらに象牙質ディスクを超音波洗浄し(30分×2回)、象牙質のスミヤー層を取り除き、これをサンプルとした。各実施例および比較例の練歯磨組成物10gと、1mM相当のCaCl2、3mM相当のKH2PO4および1.0単位/mLの酸性フォスファターゼを含むpH7.0の人工唾液20gとを、混合し、3倍希釈液とし、これを処置液とした。なお、3倍希釈は、歯磨き時に練歯磨組成物が唾液によって3倍に希釈されることを想定したことによる。この処置液にサンプルを3分間浸漬し、蒸留水で軽くすすいだ後、余分な処置液を除去し上記人工唾液中に37℃で12時間浸漬した。同様の操作を1日2回行ない、この一連の操作を合計5日間繰り返した。 A 1 mm thick dentin disc was cut out from the crown of a human molar tooth and polished with water-resistant abrasive paper # 4000. Further, the dentin disc was ultrasonically cleaned (30 minutes × 2 times) to remove the dentin smear layer, and this was used as a sample. The toothpaste composition of each Example and Comparative Example was mixed with 10 g of artificial saliva of pH 7.0 containing 1 mM CaCl 2 , 3 mM equivalent KH 2 PO 4 and 1.0 unit / mL acid phosphatase. A 3-fold diluted solution was used as a treatment solution. The 3-fold dilution is based on the assumption that the toothpaste composition is diluted 3-fold with saliva when brushing. The sample was immersed in this treatment solution for 3 minutes, rinsed lightly with distilled water, then the excess treatment solution was removed and immersed in the artificial saliva at 37 ° C. for 12 hours. The same operation was performed twice a day, and this series of operations was repeated for a total of 5 days.
最終日に、サンプルを蒸留水でよく濯ぎ、常温で一晩乾燥した。この処置前および処置後のサンプルの表面の微小硬度変化を、ダイナミック超微小硬度計(DUH−211S、島津製作所製)により測定した。試験条件は、負荷:50mN、負荷保持時間:3秒、硬度値:1サンプルあたり5箇所の負荷除荷試験平均値とした。下記式(4)において、処置前の平均硬度とは、各実施例および比較例の練歯磨組成物および人工唾液処理前のサンプル内5箇所の硬度の平均値を示す。処置後の平均硬度とは、各実施例および比較例の練歯磨組成物・人工唾液処理後のサンプル内5箇所の硬度の平均値を示す。 On the last day, the sample was rinsed well with distilled water and dried overnight at ambient temperature. The change in microhardness of the surface of the sample before and after the treatment was measured with a dynamic ultra-microhardness meter (DUH-211S, manufactured by Shimadzu Corporation). The test conditions were as follows: load: 50 mN, load holding time: 3 seconds, hardness value: average value of 5 load unloading tests per sample. In the following formula (4), the average hardness before treatment refers to the average value of the hardness of the toothpaste compositions of the examples and comparative examples and the hardness at five locations in the sample before artificial saliva treatment. The average hardness after treatment refers to the average value of the hardness at 5 locations in the sample after the toothpaste composition / artificial saliva treatment of each example and comparative example.
〔式(4)〕
象牙質硬度増加率(%)=
((処置前の平均硬度)−(処置後の平均硬度))/処置前の平均硬度×100
[Formula (4)]
Dentin hardness increase rate (%) =
((Average hardness before treatment) − (Average hardness after treatment)) / Average hardness before treatment × 100
下記評価基準4により、上記式(4)で算出される象牙質硬度増加率から、実施例および比較例の練歯磨組成物を含む処置液による、上記処置後の象牙質耐酸性の向上の程度を評価し、表1−1〜1−5に示した。なお、一連の実験操作は、各実施例および比較例につきN=3で行い、評価基準4による評価には、象牙質硬度増加率の平均値を採用した。 From the dentin hardness increase rate calculated by the above formula (4) according to the following evaluation criteria 4, the degree of improvement in dentin acid resistance after the treatment by the treatment liquid containing the toothpaste compositions of Examples and Comparative Examples Are shown in Tables 1-1 to 1-5. In addition, a series of experiment operation was performed by N = 3 for each Example and the comparative example, and the average value of the dentin hardness increase rate was employ | adopted for the evaluation by the evaluation criteria 4. FIG.
〔評価基準4〕
◎:象牙質硬度増加率が30%以上
○:象牙質硬度増加率が20%以上30%未満
△:象牙質硬度増加率が10%以上20%未満
×:象牙質硬度増加率が10%未満
[Evaluation criteria 4]
◎: Dentin hardness increase rate is 30% or more ○: Dentin hardness increase rate is 20% or more and less than 30% △: Dentin hardness increase rate is 10% or more and less than 20% ×: Dentin hardness increase rate is less than 10%
表1−1〜1−5から明らかなとおり、実施例の練歯磨組成物の評価は、比較例の練歯磨組成物の評価と比較して優れていた。この結果は、本発明の口腔用組成物が、象牙質表面に無機質を沈着させ、象牙細管を封鎖し脱灰を抑制する作用を有し、これにより象牙質が露出していた部分をエナメル質に近い状態として、象牙質の硬さを顕著に向上させることができることを示す。 As is clear from Tables 1-1 to 1-5, the evaluation of the toothpaste compositions of the examples was superior to the evaluation of the toothpaste compositions of the comparative examples. As a result, the composition for oral cavity of the present invention has an action of depositing an inorganic substance on the surface of the dentin, sealing the dentinal tubule and suppressing decalcification, and thereby the portion where the dentin is exposed is enamel. It shows that the hardness of dentine can be remarkably improved as a state close to.
実験例4および5の結果は、本発明の口腔用組成物が、露出した脆弱な象牙質を化学的および物理的に強化する機能に優れ、象牙質う蝕に対する高い予防効果、中でも根面う蝕に対する高い予防効果を有することを示す。 The results of Experimental Examples 4 and 5 show that the oral composition of the present invention is excellent in the function of chemically and physically strengthening the exposed fragile dentin, and has a high preventive effect on dentin caries, among others. It has a high preventive effect on caries.
〔実験例5.使用感の評価〕
パネラー10名を用い、実施例および比較例の練歯磨組成物について使用感の評価を行なった。具体的には、各練歯磨組成物を約1cm歯ブラシの上に乗せ、3分間磨いてもらい、水ですすいだ。ブラッシング後、各実施例および比較例の使用感および使用後の後味の悪さについてアンケートを行ない、下記評価基準5−1に従い、評点化した。
[Experimental Example 5. (Evaluation of feeling of use)
Ten panelists were used to evaluate the feeling of use of the toothpaste compositions of Examples and Comparative Examples. Specifically, each toothpaste composition was placed on a toothbrush of about 1 cm, brushed for 3 minutes, and rinsed with water. After brushing, a questionnaire was conducted on the feeling of use of each example and comparative example and the poor aftertaste after use, and scored according to the following evaluation criteria 5-1.
〔評価基準5−1;各被験者の評点〕
4点:良い
3点:やや良い
2点:やや悪い
1点:悪い
[Evaluation Criteria 5-1: Score of each subject]
4 points: good 3 points: somewhat good 2 points: somewhat bad 1 point: bad
さらに、各実施例および比較例とも、評価基準5−1に基づく評点について、パネラー10名(N=10)の平均値を求め、下記の評価基準5−2に基づき4段階評価を行い、該評価を表1−1〜1−5に示した。 Further, in each of the examples and comparative examples, the average value of 10 panelists (N = 10) is obtained for the score based on the evaluation criterion 5-1, and the four-stage evaluation is performed based on the following evaluation criterion 5-2. The evaluation is shown in Tables 1-1 to 1-5.
〔評価基準5−2;10名の平均値〕
◎:3.5点以上
○:3.0点以上3.5点未満
△:2.0点以上3.0点未満
×:2.0点未満
[Evaluation Criteria 5-2; Average of 10 persons]
◎: 3.5 points or more ○: 3.0 points or more and less than 3.5 points △: 2.0 points or more and less than 3.0 points ×: Less than 2.0 points
表1−1〜1−5から明らかなとおり、実施例の練歯磨組成物の評価は、比較例の練歯磨組成物の評価と比較して優れていた。この結果は、本発明の口腔用組成物が、組成物中に含まれる塩類の金属味および塩味が隠蔽されており、使用感に優れることを示す。 As is clear from Tables 1-1 to 1-5, the evaluation of the toothpaste compositions of the examples was superior to the evaluation of the toothpaste compositions of the comparative examples. This result shows that the oral cavity composition of the present invention is excellent in usability because the metal taste and saltiness of the salts contained in the composition are concealed.
実施例38〜43〔練歯磨組成物〕
実施例1と同様の手順で、下記の各組成の練歯磨組成物を調製した。
Examples 38 to 43 [Toothpaste composition]
In the same procedure as in Example 1, toothpaste compositions having the following compositions were prepared.
〔実施例38の練歯磨組成物の組成〕
(A):乳清 1.4質量%(固形分として0.1質量%)
(FMエキスLA(固形分濃度:7質量%)、一丸ファルコス(株)製)
(B):フッ化ナトリウム 0.21質量%(フッ素として950ppm)
(C):リン酸二水素カリウム 5.0質量%
無水ケイ酸 10.0質量%
ラウリル硫酸ナトリウム 1.0質量%
プロピレングリコール 3.0質量%
アルギン酸ナトリウム 0.3質量%
ポリアクリル酸ナトリウム 0.4質量%
70質量%ソルビトール 30.0質量%
サッカリンナトリウム 0.01質量%
香料 0.5質量%
メチルパラベン 0.15質量%
水酸化ナトリウム 適量
精製水 残
合計 100質量%
(A)/(C)の質量比:0.02、pH 7.0
[Composition of the toothpaste composition of Example 38]
(A): Whey 1.4% by mass (0.1% by mass as solid content)
(FM extract LA (solid content concentration: 7% by mass), manufactured by Ichimaru Falcos)
(B): Sodium fluoride 0.21% by mass (950 ppm as fluorine)
(C): Potassium dihydrogen phosphate 5.0% by mass
Silica anhydride 10.0% by mass
Sodium lauryl sulfate 1.0 mass%
Propylene glycol 3.0% by mass
Sodium alginate 0.3% by mass
Sodium polyacrylate 0.4% by mass
70% by mass Sorbitol 30.0% by mass
Saccharin sodium 0.01% by mass
Fragrance 0.5% by mass
Methylparaben 0.15% by mass
Sodium hydroxide appropriate amount Purified water remaining
Total 100% by mass
(A) / (C) mass ratio: 0.02, pH 7.0
〔実施例39の練歯磨組成物の組成〕
(A):乳清 1.04質量%(固形分として1.0質量%)
(ホエイパウダーDX(固形分濃度:96質量%)、森永乳業(株)製)
(B):フッ化ナトリウム 0.21質量%(フッ素として950ppm)
(C):硫酸ナトリウム 5.0質量%
無水ケイ酸 10.0質量%
ラウリル硫酸ナトリウム 1.0質量%
プロピレングリコール 3.0質量%
アルギン酸ナトリウム 0.3質量%
ポリアクリル酸ナトリウム 0.4質量%
70質量%ソルビトール 30.0質量%
サッカリンナトリウム 0.01質量%
香料 0.5質量%
メチルパラベン 0.15質量%
水酸化ナトリウム 適量
精製水 残
合計 100質量%
(A)/(C)の質量比:0.2、pH 7.5
[Composition of the toothpaste composition of Example 39]
(A): Whey 1.04% by mass (1.0% by mass as solid content)
(Whey powder DX (solid content concentration: 96 mass%), manufactured by Morinaga Milk Industry Co., Ltd.)
(B): Sodium fluoride 0.21% by mass (950 ppm as fluorine)
(C): Sodium sulfate 5.0 mass%
Silica anhydride 10.0% by mass
Sodium lauryl sulfate 1.0 mass%
Propylene glycol 3.0% by mass
Sodium alginate 0.3% by mass
Sodium polyacrylate 0.4% by mass
70% by mass Sorbitol 30.0% by mass
Saccharin sodium 0.01% by mass
Fragrance 0.5% by mass
Methylparaben 0.15% by mass
Sodium hydroxide appropriate amount Purified water remaining Total 100% by mass
(A) / (C) mass ratio: 0.2, pH 7.5
〔実施例40の練歯磨組成物の組成〕
(A):ラクトフェリン 1.0質量%(固形分として1.0)
(ラクトフェリンEX(固形分濃度:100質量%)、森永乳業(株)製)
(B):フッ化ナトリウム 0.21質量%(フッ素として950ppm)
(C):硝酸カリウム 5.0質量%
無水ケイ酸 10.0質量%
ラウリル硫酸ナトリウム 1.0質量%
プロピレングリコール 3.0質量%
アルギン酸ナトリウム 0.3質量%
ポリアクリル酸ナトリウム 0.4質量%
デキストラナーゼ 0.2質量%
70質量%ソルビトール 30.0質量%
サッカリンナトリウム 0.01質量%
香料 0.5質量%
メチルパラベン 0.15質量%
水酸化ナトリウム 適量
精製水 残
合計 100質量%
(A)/(C)の質量比:0.2、pH 8.0
[Composition of the toothpaste composition of Example 40]
(A): Lactoferrin 1.0 mass% (1.0 as solid content)
(Lactoferrin EX (solid content concentration: 100% by mass), manufactured by Morinaga Milk Industry Co., Ltd.)
(B): Sodium fluoride 0.21% by mass (950 ppm as fluorine)
(C): Potassium nitrate 5.0% by mass
Silica anhydride 10.0% by mass
Sodium lauryl sulfate 1.0 mass%
Propylene glycol 3.0% by mass
Sodium alginate 0.3% by mass
Sodium polyacrylate 0.4% by mass
Dextranase 0.2% by mass
70% by mass Sorbitol 30.0% by mass
Saccharin sodium 0.01% by mass
Fragrance 0.5% by mass
Methylparaben 0.15% by mass
Sodium hydroxide appropriate amount Purified water remaining Total 100% by mass
(A) / (C) mass ratio: 0.2, pH 8.0
〔実施例41の練歯磨組成物の組成〕
(A):ラクトフェリン 1.0質量%(固形分として1.0質量%)
(ラクトフェリンEX(固形分濃度:100質量%)、森永乳業(株)製)
(B):フッ化ナトリウム 0.21質量%(フッ素として950ppm)
(C):硝酸カリウム 5.0質量%
無水ケイ酸 10.0質量%
ラウリル硫酸ナトリウム 1.0質量%
プロピレングリコール 3.0質量%
アルギン酸ナトリウム 0.3質量%
ポリアクリル酸ナトリウム 0.4質量%
イソプロピルメチルフェノール 0.02質量%
70質量%ソルビトール 30.0質量%
サッカリンナトリウム 0.01質量%
香料 0.5質量%
メチルパラベン 0.15質量%
水酸化ナトリウム 適量
精製水 残
合計 100質量%
(A)/(C)の質量比:0.2、pH 8.0
[Composition of the toothpaste composition of Example 41]
(A): Lactoferrin 1.0 mass% (1.0 mass% as solid content)
(Lactoferrin EX (solid content concentration: 100% by mass), manufactured by Morinaga Milk Industry Co., Ltd.)
(B): Sodium fluoride 0.21% by mass (950 ppm as fluorine)
(C): Potassium nitrate 5.0% by mass
Silica anhydride 10.0% by mass
Sodium lauryl sulfate 1.0 mass%
Propylene glycol 3.0% by mass
Sodium alginate 0.3% by mass
Sodium polyacrylate 0.4% by mass
Isopropylmethylphenol 0.02% by mass
70% by mass Sorbitol 30.0% by mass
Saccharin sodium 0.01% by mass
Fragrance 0.5% by mass
Methylparaben 0.15% by mass
Sodium hydroxide appropriate amount Purified water remaining Total 100% by mass
(A) / (C) mass ratio: 0.2, pH 8.0
〔実施例42の練歯磨組成物の組成〕
(A):乳清 1.04質量%(固形分として1.0質量%)
(ホエイパウダーDX(固形分濃度:96質量%)、森永乳業(株)製)
(B):フッ化ナトリウム 0.21質量%(フッ素として950ppm)
(C):硝酸カリウム 5.0質量%
無水ケイ酸 10.0質量%
ラウリル硫酸ナトリウム 1.0質量%
プロピレングリコール 3.0質量%
アルギン酸ナトリウム 0.3質量%
ポリアクリル酸ナトリウム 0.4質量%
塩化セチルピリジニウム 0.05質量%
70質量%ソルビトール 30.0質量%
サッカリンナトリウム 0.01質量%
香料 0.5質量%
メチルパラベン 0.15質量%
水酸化ナトリウム 適量
精製水 残
合計 100質量%
(A)/(C)の質量比:0.2、pH 7.5
[Composition of the toothpaste composition of Example 42]
(A): Whey 1.04% by mass (1.0% by mass as solid content)
(Whey powder DX (solid content concentration: 96 mass%), manufactured by Morinaga Milk Industry Co., Ltd.)
(B): Sodium fluoride 0.21% by mass (950 ppm as fluorine)
(C): Potassium nitrate 5.0% by mass
Silica anhydride 10.0% by mass
Sodium lauryl sulfate 1.0 mass%
Propylene glycol 3.0% by mass
Sodium alginate 0.3% by mass
Sodium polyacrylate 0.4% by mass
Cetylpyridinium chloride 0.05% by mass
70% by mass Sorbitol 30.0% by mass
Saccharin sodium 0.01% by mass
Fragrance 0.5% by mass
Methylparaben 0.15% by mass
Sodium hydroxide appropriate amount Purified water remaining Total 100% by mass
(A) / (C) mass ratio: 0.2, pH 7.5
〔実施例43の練歯磨組成物の組成〕
(A):乳清 1.4質量%(固形分として0.1質量%)
(FMエキスLA(固形分濃度:7質量%)、一丸ファルコス(株)製)
(B):フッ化ナトリウム 0.21質量%(フッ素として950ppm)
(C):リン酸二水素カリウム 3.0質量%
無水ケイ酸 10.0質量%
ラウリル硫酸ナトリウム 1.0質量%
プロピレングリコール 3.0質量%
アルギン酸ナトリウム 0.3質量%
ポリアクリル酸ナトリウム 0.4質量%
70質量%ソルビトール 30.0質量%
キシリトール 10.0質量%
サッカリンナトリウム 0.01質量%
香料 0.5質量%
メチルパラベン 0.15質量%
水酸化ナトリウム 適量
精製水 残
合計 100質量%
(A)/(C)の質量比:0.03、pH 7.2
[Composition of the toothpaste composition of Example 43]
(A): Whey 1.4% by mass (0.1% by mass as solid content)
(FM extract LA (solid content concentration: 7% by mass), manufactured by Ichimaru Falcos)
(B): Sodium fluoride 0.21% by mass (950 ppm as fluorine)
(C): Potassium dihydrogen phosphate 3.0% by mass
Silica anhydride 10.0% by mass
Sodium lauryl sulfate 1.0 mass%
Propylene glycol 3.0% by mass
Sodium alginate 0.3% by mass
Sodium polyacrylate 0.4% by mass
70% by mass Sorbitol 30.0% by mass
Xylitol 10.0% by mass
Saccharin sodium 0.01% by mass
Fragrance 0.5% by mass
Methylparaben 0.15% by mass
Sodium hydroxide appropriate amount Purified water remaining Total 100% by mass
(A) / (C) mass ratio: 0.03, pH 7.2
実施例44〜46〔洗口組成物の調製〕
スリーワンモーターと回転羽根を有する撹拌機を装着したステンレス製容器に、規定量の精製水を投入し、配合成分のうち乳清、ラクトフェリン、フッ化ナトリウム、モノフルオロリン酸ナトリウム、硝酸カリウム、硝酸ナトリウム、ソルビトールなどの水溶性成分を撹拌しながら投入、溶解させた。一方、スリーワンモーターと回転羽根を有する撹拌機を装着した別のステンレス製容器に、規定量のエタノール等の有機溶剤を投入し、配合成分のうち香料、メチルパラベン等の油溶性成分を撹拌しながら投入、溶解させた。更に、水溶性成分を溶解させた容器に、油溶性成分を加えて30分撹拌し、均一溶液とし洗口液1.0kgを得た。
Examples 44 to 46 [Preparation of mouthwash composition]
Put a specified amount of purified water into a stainless steel container equipped with a three-one motor and a stirrer with rotating blades. Among the ingredients, whey, lactoferrin, sodium fluoride, sodium monofluorophosphate, potassium nitrate, sodium nitrate, Water-soluble components such as sorbitol were added and dissolved while stirring. On the other hand, in a separate stainless steel container equipped with a three-one motor and a stirrer with rotating blades, a specified amount of organic solvent such as ethanol is added and oil-soluble components such as fragrance and methylparaben are added while stirring. , Dissolved. Further, the oil-soluble component was added to the container in which the water-soluble component was dissolved, and the mixture was stirred for 30 minutes to obtain a uniform solution of 1.0 kg of the mouthwash.
〔実施例44の洗口組成物の組成〕
(A):乳清 1.4質量%(固形分として0.1質量%)
(FMエキスLA(固形分濃度:7質量%)、一丸ファルコス(株)製)
(B):フッ化ナトリウム 0.044質量%(フッ素として200ppm)
(C):硝酸カリウム 5.0質量%
ポリオキシエチレン硬化ヒマシ油 2.0質量%
(平均付加EO(エチレンオキサイド平均付加モル数):60モル)
エタノール 5.0質量%
グリセリン 1.0質量%
サッカリンナトリウム 0.01質量%
香料 0.15質量%
メチルパラベン 0.3質量%
水酸化ナトリウム 適量
精製水 残
合計 100質量%
(A)/(C)の質量比:0.02、pH 7.6
[Composition of mouthwash composition of Example 44]
(A): Whey 1.4% by mass (0.1% by mass as solid content)
(FM extract LA (solid content concentration: 7% by mass), manufactured by Ichimaru Falcos)
(B): Sodium fluoride 0.044 mass% (200 ppm as fluorine)
(C): Potassium nitrate 5.0% by mass
Polyoxyethylene hydrogenated castor oil 2.0% by mass
(Average addition EO (ethylene oxide average addition mole number): 60 mol)
Ethanol 5.0% by mass
Glycerin 1.0% by mass
Saccharin sodium 0.01% by mass
Fragrance 0.15% by mass
Methylparaben 0.3% by mass
Sodium hydroxide appropriate amount Purified water remaining Total 100% by mass
(A) / (C) mass ratio: 0.02, pH 7.6
〔実施例45の洗口組成物の組成〕
(A):乳清 1.04質量%(固形分として1.0質量%)
(ホエイパウダーDX(固形分濃度:96質量%)、森永乳業(株)製)
(B):フッ化ナトリウム 0.044質量%(フッ素として200ppm)
(C):硝酸ナトリウム 5.0質量%
ポリオキシエチレン硬化ヒマシ油 2.0質量%
(平均付加EO(エチレンオキサイド平均付加モル数):60モル)
エタノール 5.0質量%
グリセリン 1.0質量%
サッカリンナトリウム 0.01質量%
香料 0.15質量%
メチルパラベン 0.3質量%
水酸化ナトリウム 適量
精製水 残
合計 100質量%
(A)/(C)の質量比:0.2、pH 7.0
[Composition of mouthwash composition of Example 45]
(A): Whey 1.04% by mass (1.0% by mass as solid content)
(Whey powder DX (solid content concentration: 96 mass%), manufactured by Morinaga Milk Industry Co., Ltd.)
(B): Sodium fluoride 0.044 mass% (200 ppm as fluorine)
(C): Sodium nitrate 5.0 mass%
Polyoxyethylene hydrogenated castor oil 2.0% by mass
(Average addition EO (ethylene oxide average addition mole number): 60 mol)
Ethanol 5.0% by mass
Glycerin 1.0% by mass
Saccharin sodium 0.01% by mass
Fragrance 0.15% by mass
Methylparaben 0.3% by mass
Sodium hydroxide appropriate amount Purified water remaining Total 100% by mass
(A) / (C) mass ratio: 0.2, pH 7.0
〔実施例46の洗口組成物の組成〕
(A):ラクトフェリン 1.0質量%(固形分として1.0質量%)
(ラクトフェリンEX(固形分濃度:100質量%)、森永乳業(株)製)
(B):フッ化ナトリウム 0.044質量%(フッ素として200ppm)
(C):塩化カリウム 5.0質量%
ポリオキシエチレン硬化ヒマシ油 2.0質量%
(平均付加EO(エチレンオキサイド平均付加モル数):60モル)
エタノール 5.0質量%
グリセリン 1.0質量%
サッカリンナトリウム 0.01質量%
香料 0.15質量%
メチルパラベン 0.3質量%
水酸化ナトリウム 適量
精製水 残
合計 100質量%
(A)/(C)の質量比:0.2、pH 7.5
[Composition of mouthwash composition of Example 46]
(A): Lactoferrin 1.0 mass% (1.0 mass% as solid content)
(Lactoferrin EX (solid content concentration: 100% by mass), manufactured by Morinaga Milk Industry Co., Ltd.)
(B): Sodium fluoride 0.044 mass% (200 ppm as fluorine)
(C): 5.0% by mass of potassium chloride
Polyoxyethylene hydrogenated castor oil 2.0% by mass
(Average addition EO (ethylene oxide average addition mole number): 60 mol)
Ethanol 5.0% by mass
Glycerin 1.0% by mass
Saccharin sodium 0.01% by mass
Fragrance 0.15% by mass
Methylparaben 0.3% by mass
Sodium hydroxide appropriate amount Purified water remaining Total 100% by mass
(A) / (C) mass ratio: 0.2, pH 7.5
Claims (8)
(B):フッ素化合物、および、
(C):硝酸、塩酸、リン酸および硫酸から選ばれる酸の、カリウム塩およびナトリウム塩よりなる群から選ばれる少なくとも1種の塩
を含有する、口腔用組成物。 (A): whey and / or lactoferrin,
(B): a fluorine compound, and
(C): An oral composition containing at least one salt selected from the group consisting of a potassium salt and a sodium salt of an acid selected from nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid.
(B):フッ素化合物、および、
(C):硝酸、塩酸、リン酸および硫酸のカリウム塩およびナトリウム塩よりなる群から選ばれる少なくとも1種
を含有する知覚過敏抑制組成物。 (A): whey and / or lactoferrin,
(B): a fluorine compound, and
(C): A hypersensitivity suppressing composition containing at least one selected from the group consisting of potassium and sodium salts of nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid.
(C):硝酸、塩酸、リン酸および硫酸のカリウム塩およびナトリウム塩よりなる群から選ばれる少なくとも1種
を含有する、フッ素化合物を含む口腔用組成物用の、可溶性フッ素化合物安定性向上組成物。 (A): whey and / or lactoferrin, and
(C): A soluble fluorine compound stability improving composition for an oral composition containing a fluorine compound containing at least one selected from the group consisting of potassium salt and sodium salt of nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid .
(B):フッ素化合物、および、
(C):硝酸、塩酸、リン酸および硫酸のカリウム塩およびナトリウム塩よりなる群から選ばれる少なくとも1種
を含有する象牙質の硬さ向上組成物。 (A): whey and / or lactoferrin,
(B): a fluorine compound, and
(C): Dentin hardness-improving composition containing at least one selected from the group consisting of potassium salt and sodium salt of nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid.
(B):フッ素化合物、および、
(C):硝酸、塩酸、リン酸および硫酸のカリウム塩およびナトリウム塩よりなる群から選ばれる少なくとも1種
を含有する象牙質の耐酸性向上組成物。 (A): whey and / or lactoferrin,
(B): a fluorine compound, and
(C): A dentin acid resistance improving composition containing at least one selected from the group consisting of potassium salt and sodium salt of nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011102948A JP5709639B2 (en) | 2011-05-02 | 2011-05-02 | Oral composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011102948A JP5709639B2 (en) | 2011-05-02 | 2011-05-02 | Oral composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012232937A true JP2012232937A (en) | 2012-11-29 |
JP5709639B2 JP5709639B2 (en) | 2015-04-30 |
Family
ID=47433641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011102948A Active JP5709639B2 (en) | 2011-05-02 | 2011-05-02 | Oral composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5709639B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015083556A (en) * | 2013-10-25 | 2015-04-30 | ライオン株式会社 | Dentifrice composition |
JP2019011267A (en) * | 2017-06-29 | 2019-01-24 | キリン株式会社 | Oral composition for inhibiting stain adhesion |
JP2020176060A (en) * | 2019-04-15 | 2020-10-29 | 花王株式会社 | Oral composition |
WO2021261462A1 (en) * | 2020-06-26 | 2021-12-30 | ライオン株式会社 | Composition for oral cavity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001089339A (en) * | 1999-09-14 | 2001-04-03 | Lion Corp | Oral composition |
JP2008063334A (en) * | 2006-08-10 | 2008-03-21 | Lion Corp | Composition for attaching water soluble active ingredient and method for attaching the water soluble active ingredient |
JP2008081424A (en) * | 2006-09-27 | 2008-04-10 | Lion Corp | Tooth whitening set |
-
2011
- 2011-05-02 JP JP2011102948A patent/JP5709639B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001089339A (en) * | 1999-09-14 | 2001-04-03 | Lion Corp | Oral composition |
JP2008063334A (en) * | 2006-08-10 | 2008-03-21 | Lion Corp | Composition for attaching water soluble active ingredient and method for attaching the water soluble active ingredient |
JP2008081424A (en) * | 2006-09-27 | 2008-04-10 | Lion Corp | Tooth whitening set |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015083556A (en) * | 2013-10-25 | 2015-04-30 | ライオン株式会社 | Dentifrice composition |
WO2015060426A1 (en) * | 2013-10-25 | 2015-04-30 | ライオン株式会社 | Tooth paste composition |
JP2019011267A (en) * | 2017-06-29 | 2019-01-24 | キリン株式会社 | Oral composition for inhibiting stain adhesion |
JP2023024696A (en) * | 2017-06-29 | 2023-02-16 | キリンホールディングス株式会社 | Oral composition for suppressing stain adhesion |
JP2020176060A (en) * | 2019-04-15 | 2020-10-29 | 花王株式会社 | Oral composition |
JP7283960B2 (en) | 2019-04-15 | 2023-05-30 | 花王株式会社 | oral composition |
JP2023096107A (en) * | 2019-04-15 | 2023-07-06 | 花王株式会社 | oral composition |
JP7561915B2 (en) | 2019-04-15 | 2024-10-04 | 花王株式会社 | Oral Composition |
WO2021261462A1 (en) * | 2020-06-26 | 2021-12-30 | ライオン株式会社 | Composition for oral cavity |
JP7635508B2 (en) | 2020-06-26 | 2025-02-26 | ライオン株式会社 | Oral Composition |
Also Published As
Publication number | Publication date |
---|---|
JP5709639B2 (en) | 2015-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7218934B2 (en) | Stabilized stannous composition | |
JP5613990B2 (en) | Tooth dentinal tubule sealant and oral composition | |
JP6471667B2 (en) | Liquid oral composition | |
WO2003003994A1 (en) | Oral preparation | |
JP5709639B2 (en) | Oral composition | |
JP5720546B2 (en) | Dentifrice composition and tooth remineralization accelerator | |
WO2019107332A1 (en) | Oral stain removing agent, oral stain formation inhibiting agent, and oral composition | |
KR101624764B1 (en) | Dentifrice composition | |
JP5488096B2 (en) | Oral composition | |
JPH1017449A (en) | Composition for hyperesthesia | |
JP5663893B2 (en) | Oral composition | |
JP5035512B2 (en) | Oral composition | |
JP7447470B2 (en) | dentifrice composition | |
JPH085772B2 (en) | Oral composition | |
JP4826790B2 (en) | Oral composition containing hydrolyzed silk | |
JP2015516982A5 (en) | ||
KR102563328B1 (en) | Dentifrice composition | |
WO1998042297A1 (en) | Method of recalcifying teeth | |
JP7347916B2 (en) | dentifrice composition | |
JP4656293B2 (en) | Oral composition | |
JP3803868B2 (en) | Oral composition | |
JP7027315B2 (en) | Oral composition | |
JP2006347986A (en) | Composition for oral cavity | |
CN111479553B (en) | Oral composition | |
JPH069354A (en) | Composition for oral cavity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140128 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140509 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140930 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141028 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150217 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150303 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5709639 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |